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Vitamin D is an important 
regulator of gene expression. 
Epidemiological evidence suggests 
a protective role of vitamin 
D against various diseases. 
Therefore, the molecular basis of 
vitamin D signaling needs to be 
elucidated. This thesis investigated 
the regulation of key vitamin D 
target genes, in order to provide 
further insight into the role of 
vitamin D in cancer and immunity. 
In this context it was found that 
certain vitamin D target genes 
can be used as biomarkers for 
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1,25(OH)2D3   1,25-­‐‑dihydroxyvitamin  D3  
25(OH)D3   25-­‐‑hydroxyvitamin  D3  
ASAP2   ArfGAP  with  SH3  domain,  ankyrin  repeat  and  PH  domain  2  
CDK   cyclin-­‐‑dependent  kinase  
CDKI   CDK  inhibitor  
CDKN1A   cyclin-­‐‑dependent  kinase  inhibitor  1A  
CD14   cluster  of  differentiation  14  
ChIA-­‐‑PET   chromatin  interaction  analysis  with  paired-­‐‑end  tag  sequencing  
ChIP   chromatin  immunoprecipitation  
ChIP-­‐‑seq   ChIP-­‐‑sequencing  
CTCF   CCCTC-­‐‑binding  factor  
CXCL   chemokine  CXC  motif  ligand  
CYP24A1   cytochrome  P450,  family  24,  subfamily  A,  polypeptide  1  
DBD   DNA-­‐‑binding  domain  
DUSP10   dual  specificity  phosphatase  10  
DR3   direct  repeat  spaced  by  3  nucleotides  
FBS   fetal  bovine  serum  
FAIRE   formaldehyde-­‐‑assisted  isolation  of  regulatory  elements  
FAIRE-­‐‑seq   FAIRE-­‐‑sequencing  
G0S2   G0/G1  switch  2  
H3K4me   histone  3  lysine  4  methylation  
HDAC   histone  deacetylase  
HUVEC   human  umbilical  vein  endothelial  cells  
IFN-­‐‑γ   interferon-­‐‑γ  
IGF   insulin-­‐‑like  growth  factor  
IGFBP   insulin-­‐‑like  growth  factor  binding  protein  
IL   interleukin  
XVI 
  
IκBα   NF-­‐‑κB  inhibitor  
LBD   ligand-­‐‑binding  domain  
LBP   ligand-­‐‑binding  pocket  
LPS   lipopolysaccharide  
MYC   v-­‐‑myc  avian  myelocytomatosis  viral  oncogene  homolog  
NF-­‐‑κB   nuclear  factor-­‐‑κB  
NR   nuclear  receptor  
NRIP1   nuclear  receptor  interacting  protein  1  
NHEK   normal  human  epidermal  keratinocytes  
PBMC   peripheral  blood  mononuclear  cell  
PBS   phosphate  buffered  saline  
qPCR   real-­‐‑time  quantitative  polymerase  chain  reaction  
PMA   phorbol  12-­‐‑myristate  13-­‐‑acetate  
PTH   parathyroid  hormone  
RXR   retinoid  X  receptor  
SGBS   Simpson-­‐‑Golabi-­‐‑Behmel  syndrome  
siRNA   small  interfering  RNA  
TGF-­‐‑β   transforming  growth  factor-­‐‑β  
THBD   thrombomodulin  
TLR   Toll-­‐‑like  receptor  
TRAK1   trafficking  protein,  kinesin  binding  1  
TSS   transcription  start  site  
UVB   ultraviolet  B  
VDR   vitamin  D  receptor  
     
    
1  Introduction  
Vitamin   D3   is   the   precursor   of   the   biologically   most   active   vitamin   D   metabolite,   1,25-­‐‑
dihydroxyvitamin  D3  (1,25(OH)2D3).  Despite  its  name,  vitamin  D3  can  be  synthetized  in  the  
skin  using  the  energy  of  ultraviolet  B  (UVB)  radiation  from  the  sun.  Vitamin  D3  production  
in  the  skin  may  not  be  adequate  to  maintain  proper  vitamin  D  status,  due  to  the  seasonal  
lack  of  sunlight  at  higher   latitude  and/or  personal   lifestyle.  This   is  a  common  problem  as  
epidemiological  studies,  analyzing  circulating  levels  of   the  storage  form  of  vitamin  D,  25-­‐‑
hydroxyvitamin  D3  (25(OH)D3),  have  revealed  that  a  low  vitamin  D  status  may  affect  more  
than  one-­‐‑third  of  the  global  population  (1).  
The  main  physiological  role  of  1,25(OH)2D3  is  to  maintain  calcium  homeostasis,  in  order  
to   prevent   bone   loss   (2).   In   addition,   epidemiological   evidence   suggests   that   functional  
vitamin  D  signaling  may  protect  against  various  diseases,   including  cancers,  autoimmune  
diseases  and  even  the  risk  of  all-­‐‑cause  death  (3).  However,  epidemiological  studies  have  not  
provided  a  mechanistic   explanation   for   the  protective   role  of  vitamin  D.  Therefore,  more  
insight  into  the  molecular  actions  of  1,25(OH)2D3  is  needed  in  order  to  better  appreciate  the  
physiological  impact  of  the  hormone.  
All  biological  actions  of  1,25(OH)2D3  are  mediated  through  the  vitamin  D  receptor  (VDR)  
in   the  nucleus.  VDR   is   a   transcription   factor   and   a  member   of   the  nuclear   receptor   (NR)  
superfamily  that  binds  directly  to  genomic  DNA  and  is  activated  through  the  high  affinity  
binding   of   1,25(OH)2D3.   Binding   leads   to   transcriptional   activation   and   rapid   changes   in  
mRNA  levels  of  primary  VDR  target  genes.  Thus,  understanding  the  physiological  effects  
of   1,25(OH)2D3   requires  knowledge  on  genomic  VDR  binding   loci   and   the  genes   that   are  
regulated  by  VDR.  Furthermore,  in  each  1,25(OH)2D3  target  tissue,  VDR  binds  to  thousands  
of  genomic  regions.  Thus,  1,25(OH)2D3  has  the  potential  to  regulate  directly  multiple  tissue-­‐‑
specific  target  genes.  
A  number  of  primary  1,25(OH)2D3  target  genes  have  been  identified  to  be  involved  in  the  
regulation   of   a   wide   range   of   physiological   functions   in   different   human   tissues.   For  
example,   1,25(OH)2D3   regulates   immuno-­‐‑modulatory   cytokines,   transcription   factors   and  
the   genes   controlling   cellular   growth.   This   emphasizes   the   pleiotropic   nature   of   the  
hormone.   However,   recent   studies   of   genome-­‐‑wide   VDR   binding   sites   have   revealed  
thousands  of  new  genomic  VDR  binding  sites  with  unknown  impact  on  gene  regulation.  In  
addition,   already   known   1,25(OH)2D3   target   genes  may   be   regulated   by   far  more   distant  
VDR  binding  sites  than  previously  estimated.  
This  doctoral  thesis  was  carried  out  to  extend  our  understanding  of  the  mechanistic  basis  
and   gene   regulatory   scenarios   of   VDR-­‐‑mediated   gene   regulation.   The   study   revealed  
mechanistic   differences   between   1,25(OH)2D3   and   its   synthetic   analog,   Gemini,   in   VDR-­‐‑
mediated   gene   regulation   in   non-­‐‑malignant   human   breast   epithelial   cells.   In   a   human  
monocytic  cell  line,  several  genomic  regions  and  primary  1,25(OH)2D3  target  genes,  which  
are  involved  in  the  control  of  cellular  growth  and  immune  function,  were  characterized  in  
detail.  Finally,  cross  tissue  conserved  1,25(OH)2D3  target  genes  were  studied  in  adipocytes  
demonstrating  the  possibility  to  use  these  genes  as  biomarkers  for  the  actions  of  vitamin  D3  
in  human  individuals.  




2  Review  of  the  Literature  
2.1 VITAMIN D METABOLISM 
2.1.1  Sources  and  metabolism  
The   secosteroid   vitamin   D3   is   a   biologically   inactive   precursor   from   which   the   actual  
hormone,  1,25(OH)2D3,  also  known  as  calcitriol,  is  derived.  Vitamin  D3  is  synthetized,  when  
the  skin  is  exposed  to  sunlight.  Then  the  energy  of  UVB  radiation  converts   in  a  multistep  
process  7-­‐‑dehydrocholesterol  into  vitamin  D3.  In  addition,  vitamin  D  can  be  obtained  from  
diet,  mainly  from  animal  origin,  such  as  fatty  fish,  liver,  eggs  or  fortified  dairy  products,  or  
from  dietary  supplements.  Vitamin  D3  can  be  stored  in  the  liver  and  in  adipose  tissue  and  is  
released  when   it   is   not   adequately   produced   or   obtained   from   diet   (4).   Vitamin  D2,   also  
known  as  ergocalciferol,  is  a  form  of  vitamin  D  that  is  obtained  only  from  dietary  sources,  
mainly  from  plants  and  fungi.  Vitamin  D2  is  biologically  less  active  than  vitamin  D3.  Due  to  
limited   dietary   sources   of   vitamin   D2,   the   main   vitamin   D   form   in   humans   and   other  
animals  is  vitamin  D3  (4,5).  
Two  hydroxylation  steps  are  needed  for  the  synthesis  of  the  biologically  active  form  of  
vitamin  D3.  First,  vitamin  D3  is  25-­‐‑hydroxylated,  mainly  in  the  liver  by  the  cytochrome  P450  
(CYP)  enzymes  CYP27A1  or  CYP2R1,  to  yield  25(OH)D3  (6).  25(OH)D3  is  an  inactive  form  
of  vitamin  D3  and  its  serum  levels  are  often  used  to  determine  and  monitor  the  vitamin  D  
status  of  human  individuals  (7).  25(OH)D3  is  hydroxylated  by  the  1α-­‐‑hydroxylase  enzyme  
CYP27B1,   to   yield   1,25(OH)2D3,   which   is   the   active   hormone   and   responsible   for   the  
physiological   actions   of   vitamin  D3   (6).  All   vitamin  D  metabolites   are   transported   in   the  
circulation   bound   to   the   vitamin   D-­‐‑binding   protein.   The   hydroxylation   of   25(OH)D3   to  
1,25(OH)2D3  occurs  mainly  in  the  kidneys  and  is  tightly  regulated  by  parathyroid  hormone  
(PTH).   In   addition,   extra-­‐‑renal   CYP27B1   activity   is   mediating   tissue-­‐‑specific   and  
intracellular  increase  in  1,25(OH)2D3  levels.  Inactivation  of  both  1,25(OH)2D3  and  25(OH)D3  
is  achieved  by  24-­‐‑hydroxylation,  carried  out  by  the  cytochrome  P450,  family  24,  subfamily  
A,   polypeptide   1   (CYP24A1)   enzyme,   and   results   in   the  metabolites   1,24,25(OH)3D3   and  
24,25(OH)2D3,   respectively.   These   metabolites   are   after   multiple   hydroxylation   steps  
degraded  into  the  water-­‐‑soluble  inactive  compounds  calcitroic  acid  or  a  26,23-­‐‑lactone.  
In   summary,   the   renal   ratio   of   the   activating   CYP27B1   and   inactivating   CYP24A1  
enzymes   determines   systemic   1,25(OH)2D3   and   25(OH)D3   levels,   whilst   tissue-­‐‑specific  
CYP24A1  together  with  CYP27B1  regulates  local  1,25(OH)2D3  levels.  In  addition,  CYP24A1  
is   the   rate-­‐‑limiting   enzyme   for   1,25(OH)2D3   concentrations,   since   the   CYP24A1   gene  
expression  is  strongly  induced  by  1,25(OH)2D3  in  multiple  tissues.  All  steps  of  the  metabolic  
cascade  are  presented  in  Figure  1.  




Figure 1. Vitamin D3 metabolism. Vitamin D3 is converted to the inactive circulating storage 
form 25(OH)D3 mainly in the liver. 25(OH)D3 is further metabolized into the active hormone, 
1,25(OH)2D3. Both vitamin D metabolites are inactivated by 24-hydroxylation. 
2.1.2  Vitamin  D  status  in  humans  
Serum   25(OH)D   concentration   (meaning   here   the   sum   of   both   25(OH)D3   and   25(OH)D2,  
although   generally   25(OH)D3   is   far   more   abundant   in   most   human   individuals)   is   the  
established   measure   for   the   vitamin   D   status   of   human   individuals   and   is   used   to  
determine  the  need  of  supplementation  with  vitamin  D  (7).  In  accordance,  serum  25(OH)D  
concentration  below  50  nM  are  considered  as  insufficiency  in  vitamin  D  and  below  30  nM  




























































In  contrast,  the  Endocrine  Society  suggests  that  25(OH)D  levels  should  be  at  least  75  nM  (9).  
In  Finland,   the  Hospital  District  of  Helsinki  and  Uusimaa  recommends  the   target   level  of  
serum   25(OH)D   to   be   above   50  nM   and   for   good   bone   health   the   levels   should   be   even  
above  80  nM  (10).  A  recent  systematic  review  of  195  vitamin  D  studies  involving  more  than  
168,000   individuals   from  44  countries   reported   that  37%  of   the  participants  had  25(OH)D  
serum  concentrations  below  50  nM,  and  only  11.9%  were  above  75  nM  (1).  This   indicates  
that   vitamin   D   deficiency   or   insufficiency   is   a   worldwide   problem   affecting   billions   of  
individuals.  
However,   there   are   inter-­‐‑individual   differences   in   the   amount   of   vitamin  D  
supplementation   needed,   in   order   to   maintain   adequate   25(OH)D   levels.   Moreover,   the  
recommended   doses   are   under   debate.   For   example,   the   IoM   recommends   for   healthy  
adults   15   to   20   µμg   of   daily   vitamin   D   supplementation   (8),   while   the   Endocrine   Society  
suggests   50  µμg   daily   (9).   Furthermore,   one   should   not   forget   that   human   skin   has   the  
capacity   to  generate  high  amounts  of  vitamin  D3   in   response   to   sunlight.  The  production  
rate   of   human   skin   for   vitamin   D3   depends   on   the   exposure   time   to   sunlight,   skin  
pigmentation  and  the  intensity  of  UVB  radiation,  i.e.  time  of  the  day,  latitude,  and  season.  
In  principle,  skin  is  able  to  produce  up  to  500  µμg  vitamin  D3  after  a  minimal  erythema  dose  
of  UVB  radiation,  which  can  be  as  short  as  a  10  min  of  intensive  full  body  sun  exposure  of  a  
non-­‐‑tanned  person  (4,7).  Therefore,  humans  are  able  to  maintain  adequate  vitamin  D3  levels  
through  sufficient  sun  exposure.  However,  natural  UVB  exposure  is  seasonally  very  limited  
at  higher  latitudes  (such  as  in  Finland)  or  due  to  cultural  behavior.  In  these  cases  adjusting  
sufficient  intake  of  vitamin  D  through  diet  or  supplements  is  required,  in  order  to  maintain  
healthy  vitamin  D  levels.  
Furthermore,   an   example   of   additional   complexity   in   evaluating   sufficient   intake   of  
vitamin  D,  in  order  to  maintain  a  health  effect  of  the  hormone,  is  demonstrated  by  a  recent  
study  evaluating  vitamin  D  deficiency  among  different  ethnic  groups  (11).  In  this  study,  77  
or   96%   of   black   adult   Americans   would   be   classified   as   vitamin   D-­‐‑deficient   using   a  
threshold   25(OH)D   concentration  of   50  or   75  nM,   respectively.  However,   the  black   study  
participants   had   a   higher   bone   mineral   density,   higher   calcium   levels   and   only   slightly  
higher   PTH   levels   compared   to   the   white   study   participants.   The   study   suggests   that   a  
polymorphism   in   the   gene   coding   for   the   vitamin   D-­‐‑binding   protein   among   African-­‐‑
Americans   results   in   sufficient   bioavailability   of   25(OH)D   despite   the   lower   total  
concentration  of  the  metabolite.  
Obviously,  there  is  great  variability  between  individuals  in  the  effectiveness  of  vitamin  D  
supplementation.   It   remains  unanswered  what   is   the  optimal  25(OH)D   level  and   to  what  
extent  it  is  affected  by  different  factors,  such  as  genetic  polymorphisms.  Hence,  alternative  
approaches   to   complement   the   measurement   of   the   circulating   form   of   25(OH)D   are  
required,   in   order   to   evaluate   more   precisely   the   individual   benefits   and   needs   of  
vitamin  D.  One  approach   is   to  measure  genomic   effects   of  vitamin  D  on   its   target  genes.  
Recently,   VDR   binding   sites   were   investigated   genome-­‐‑wide   in   primary   CD4+   T   cells  
isolated   from   nine   human   individuals   (12).   Serum   25(OH)D   concentration   of   the  
individuals  varied  between  22  and  107  nM.  Interestingly,  the  number  of  VDR  binding  sites  
in  T  cells  varied   largely  between  200  and  more   than  7,000,  but  correlated  with   the  serum  
25(OH)D   concentration   of   the   individuals.   This   suggests   that   the   VDR-­‐‑mediated   gene  
regulation  in  vivo  is  highly  dependent  on  the  vitamin  D  status  of  the  individual.  
A  study  that  analyzed  transcriptome-­‐‑wide  mRNA  expression  profiles  in  whole  blood  of  
more   than   200   middle-­‐‑aged   Norwegian   women   could   not   identify   a   single   gene   being  
differentially   expressed   between   vitamin  D   deficient   (25(OH)D  >  37.5  nM)   and   sufficient  
group  (25(OH)D  >  50  nM)  (13).  However,  when  they  analyzed  differentially  expressed  gene  
sets,   which   have   been   selected   from   a   large   number   of   public   datasets   of   1,25(OH)2D3-­‐‑
induced   transcriptomes   from   cell   lines,   primary   cultures,   or   xenograft   mice,   they   could  
show  that  some  of   these  gene  sets  are  differentially  expressed  between  the  groups.  When  




thrombomodulin   (THBD)   and   cluster   of   differentiation   14   (CD14)   were   the   most  
significantly  contributing  to  the  results  of  the  respective  gene  sets  correlating  to  vitamin  D  
deficiency.  Furthermore,  a  recent  study  that  monitored  71  pre-­‐‑diabetic  human  individuals  
from   the   region  of  Kuopio,   Finland,  used   combined   expression   changes   of   the   same   two  
genes  in  peripheral  blood  mononuclear  cells  (PBMCs)  and  adipocytes,  in  order  to  evaluate  
the  responsiveness  of  the  individuals  to  vitamin  D3  supplementation  (14).  The  study  found  
that  some  of  the  individuals  exhibited  a  correlation  in  the  changes  of  their  25(OH)D3  levels  
and  their  target  gene  expression  levels.  The  result  suggests  that  the  genes  CD14  and  THBD  
are   suitable   biomarkers   for   representing   the   transcriptomic   response   of   human   tissues   to  
vitamin  D3.  Transcriptomic  profiling  with  these  genes  allowed  a  categorization  of  the  study  
participants  into  responders  and  non-­‐‑responders  to  vitamin  D3.  
Taken   together,   both   studies   indicate   that   transcriptomic   responses   of   primary  
1,25(OH)2D3   target   genes   may   be   suitable   for   profiling   the   vitamin   D3   status   of   human  
individuals.  However,   further  studies  are  needed,   in  order  to  confirm  the  classification  of  
human  individuals   into  those  that  are  responding  to  vitamin  D  and  those  that  are  not.   In  
addition,   the  most   suitable   target   genes   for   representing   the   vitamin  D   status   of   human  
individuals  need  to  be  further  characterized,  in  order  to  successfully  evaluate  the  efficiency  
of  vitamin  D  supplementation.  
2.2 PHYSIOLOGICAL ROLE OF 1,25(OH)2D3 
The  biological  effects  of  1,25(OH)2D3  are  mediated  through  binding  of  the  hormone  to  the  
transcription   factor   VDR   in   the   nucleus.   VDR   binds   directly   to   genomic   DNA   and  
preferentially   to   regulatory   region   of   primary   1,25(OH)2D3   target   genes.   Subsequently,  
ligand-­‐‑activated   VDR   associates   with   the   basal   transcriptional   machinery   on   the   gene’s  
transcription  start  sites  (TSSs).  This  leads  to  transcriptional  activation,  which  is  observed  as  
rapid   increase  or  decrease   in   the  mRNA  levels  of   the  gene.  The  transcriptional  regulation  
by  1,25(OH)2D3  is  described  in  more  detail  in  chapter  2.3.  
The   best-­‐‑known   physiological   role   of   1,25(OH)2D3   is   the   regulation   of   calcium  
homeostasis   in   intestine,  bone  and  kidneys.  Severe   forms  of  vitamin  D  deficiency   lead   to  
rickets   in   children   and   osteomalacia   in   adults,   which   however   can   be   abrogated   by  
vitamin  D   supplementation   (2).   1,25(OH)2D3   enhances   intestinal   calcium   absorption   by  
directly   inducing   central   proteins   involved   in   active   intestinal   calcium   intake   (4).   Excess  
calcium   is   stored   in   the   skeleton,  which   is   the  natural   calcium  reservoir.   In   response   to  a  
decrease   in   circulating   calcium,   PTH   secretion   increases,  which   leads   to   the   induction   of  
renal  CYP27B1   expression  and  eventually   to  an   increase   in  renal  1,25(OH)2D3  production.  
This   results   ultimately   in   the   recovery   of   calcium   levels   through   increased   1,25(OH)2D3-­‐‑
mediated   calcium   absorption.   In   situations   when   dietary   calcium   is   not   available   in  
sufficient   amounts,   increased   1,25(OH)2D3   and   PTH   levels   are   able   to   stimulate   bone  
resorption  and  to  inhibit  renal  calcium  reabsorption,  in  order  to  maintain  adequate  serum  
calcium  levels  (2).  Vitamin  D3  deficiency  reduces  the  bioavailability  of  1,25(OH)2D3,  which  
causes   a   decrease   in   intestinal   calcium   absorption   and   an   increase   in   PTH   levels,   which  
eventually  increases  bone  resorption.  
Taken   together,  a   functional  vitamin  D3   system   is   required   for  maintenance  of   calcium  
homeostasis  and  healthy  bones.  
2.2.1  1,25(OH)2D3  and  cancer  
The   biological   functions   of   1,25(OH)2D3   are   not   limited   to   the   maintenance   of   calcium  
homeostasis.   VDR   and   CYP27B1   are   expressed   in   many   human   tissues   and   there   is  
accumulating  data  of  an  involvement  of  1,25(OH)2D3  in  various  physiological  functions.  A  
prospective  20-­‐‑year  follow-­‐‑up  study  of  almost  30,000  Swedish  women  described  that  their  




among  sun  avoiders  compared  with  the  sun  exposure  group  (15).  Although  the  study  did  
not  analyze  the  causes  of  death,  it  suggests  that  individuals  among  the  sun  exposure  group  
had   a   better   vitamin  D3   status   and   therefore   were   healthier.   Furthermore,   several  
epidemiological   studies   have   shown   an   association   of   a   low   25(OH)D3   status,   a   low  
vitamin  D  intake  or  a  reduced  sun  exposure  with  various  forms  of  cancer  including  those  of  
colon,  breast  and  prostate   (3,16,17).   In  addition,  molecular  and  genetic  evidence  supports  
the   protective   role   of   vitamin  D   against   cancer   (3,18).   This   suggests   that   vitamin  D  may  
inhibit   the  development  or  progression  of  various  cancers.  This   is   in  accordance  with   the  
evidence   that   solar   UVB   radiation   exposure   reduces   the   risk   for   several   cancers,   in  
particular   those   of   colon   and   breast   (19).   In   addition,   a   study   analyzing   pre-­‐‑diagnostic  
25(OH)D3   levels   among   prostate   cancer   patients   observed   that   low   25(OH)D3   levels   are  
associated   with   an   enhanced   development   of   metastatic   or   lethal   prostate   cancer   (20).  
Although   a   large   number   of   epidemiological   studies   and  meta-­‐‑analyzes   have   shown   the  
beneficial  relationship  between  vitamin  D  and  different  cancers,  not  all  studies  have  found  
an  association  with  a   low  vitamin  D  status  and  an   increased  cancer  risk   (21).   In  addition,  
randomized   controlled   trials   on   vitamin   D   supplementation   have   not   yet   provided  
adequate  information  on  the  role  of  vitamin  D  supplementation  in  cancer  prevention  (22).  
However,  epidemiological  studies  with  large  cohorts  are  subjected  to  number  of  variations,  
and  even  after  decades  of  epidemiological  evidence,  the  protective  role  of  vitamin  D  against  
cancer   development   and   progression   in   population   level   remains   elusive.   Therefore,   the  
molecular   mechanisms   and   pathways   of   vitamin   D   function   need   to   be   further  
characterized,  in  order  to  better  understand  the  protective  role  of  the  hormone.  
2.2.2  1,25(OH)2D3-­‐‑mediated  cell  cycle  inhibition  
At  the  cellular  level,  1,25(OH)2D3  directly  regulates  multiple  target  genes  involved  in  anti-­‐‑
proliferative,   pro-­‐‑differentiating   and   pro-­‐‑apoptotic   actions   in   cancer   cells.   The   central  
mechanism   for   the   anti-­‐‑proliferative   actions   of   1,25(OH)2D3   is   the   induction   of   cell   cycle  
arrest  at   the  G1  phase  of  the  cell  cycle.  Cell  cycle  progression  is  controlled  by  cyclins  and  
cyclin-­‐‑dependent   kinases   (CDKs)   that   promote   cell   cycle   phase   transitions.   In   order   to  
activate   CDKs,   the   formation   of   a   cyclin-­‐‑CDK   heterodimer   is   required.   CDK   inhibitors  
(CDKIs)   are   proteins   that   prevent   the   formation   of   an   active   cyclin-­‐‑CDK   heterodimeric  
complex   and   thereby   induce   cell   cycle   arrest   (23).   1,25(OH)2D3   directly   regulates   the  
expression  of  the  cyclin-­‐‑dependent  kinase  inhibitor  1A  (CDKN1A)  gene,  which  is  encoding  
the  CDKI  p21  (24,25).  The  CDKN1A  gene  is  discussed  in  more  detailed  in  chapter  2.4.3.  
Another  potent  CDKI,  p27,  which  is  encoded  by  the  cyclin-­‐‑dependent  kinase  inhibitor  1B  
(CDKN1B)   gene,   has   elevated   levels   in   1,25(OH)2D3-­‐‑mediated  G1   cell   cycle   arrest   (26,27).  
Observations  in  various  cancer  cell   lines  suggest  that  the  detected  up-­‐‑regulation  of  p27  in  
response  to  1,25(OH)2D3  is  mediated  through  the  stabilization  of  the  p27  protein  rather  than  
through   the   induction   of   CDKN1B   mRNA.   1,25(OH)2D3   mediates   p27   stabilization   by   a  
down-­‐‑regulation   of   the   S-­‐‑phase   kinase-­‐‑associated   protein   2   (encoded   by   the   gene  SKP2),  
which   is   responsible   for   the   initiation   of   p27  degradation   (28-­‐‑30).   Interestingly,   the  SKP2  
gene  has  been  identified  as  a  primary  VDR  target  (28).  Thus,  direct  down-­‐‑regulation  of  the  
SKP2  gene  by  1,25(OH)2D3  leads  to  increase  in  p27  levels.  This  suggest  that  slightly  elevated  
p27  levels,  which  are  often  observed  together  with  induced  p21  protein  concentrations,  are  
secondary  effects  of  1,25(OH)2D3.  Moreover,  a  study  performed  in  myeloid  HL60  and  U937  
cells  demonstrated  that  1,25(OH)2D3  down-­‐‑regulates  the  expression  of  microRNA  181  (31).  
Since   microRNA   181   directly   suppresses   CDKN1B   gene   expression,   treatment   with  
1,25(OH)2D3   leads   indirectly   to   increased   CDKN1B   mRNA   levels.   In   these   cell   lines,  
CDKN1A  has  also  been  characterized  as  a  primary  target  gene  suggesting  that  1,25(OH)2D3  
regulates  cell  cycle  inhibition  both  directly  and  indirectly  through  CDKN1A  and  CDKN1B,  
respectively.   It   should  be  noted   that   in   another   study   that   analyzed  both  p21-­‐‑/-­‐‑   and  p27-­‐‑/-­‐‑  
mouse   embryonic   fibroblasts   indicated   that   there   are   both   p27-­‐‑independent   and   p27-­‐‑




Furthermore,   treatment   of   cells   with   1,25(OH)2D3   is   associated   with   a   decrease   in  
cyclin  D1   and  E1   levels,   and   in  CDK2   activity   (26,33).  However,   these   responses  may   be  
secondary  effects  of  primary  1,25(OH)2D3  target  genes,  such  as  CDKN1A,  which  inhibit  the  
activity   of   cyclins   and   CDKs.   In   a   study   performed   on   MCF-­‐‑7   breast   cancer   cells,  
1,25(OH)2D3  suppresses  cell  proliferation  through  G1  arrest  with  temporal  elevation  of  p21  
and  p27   levels  and  a  decrease   in  cyclin  D1   levels   (26).  Moreover,  a   recent   study  suggests  
that  in  this  cell  line,  the  growth  inhibition  by  1,25(OH)2D3  is  mainly  dependent  on  insulin-­‐‑
like   growth   factor   binding   protein   3   (IGFBP3)   and   a   result   of   1,25(OH)2D3-­‐‑mediated   up-­‐‑
regulation  of   the   IGFBP3  gene   (34).   IGBFPs  are   important   regulators  of   the  availability  of  
the   circulating   insulin-­‐‑like   growth   factors   (IGF)   IGF-­‐‑I   and   IGF-­‐‑II,   which   in   turn   are  
important  mitogens  promoting   the  growth  of  normal  and  malignant   cells   (35).  The  genes  
IGFBP1,   IGFBP3   and   IGFBP5   are   primary   VDR   target   genes   (36).   The   IGF   system   is  
discussed   in  more   detail   in   chapter   2.4.1.   The   contradictory   observations   in  MCF-­‐‑7   cells  
suggests  that  the  growth  inhibition  by  1,25(OH)2D3  is  not  restricted  to  the  regulation  of  the  
central  cell  cycle  machinery,  but  that  the  hormone  simultaneously  inhibits  cellular  growth  
through  a  cross-­‐‑talk  with  other  pathways,  including  extracellular  signals.  
Collectively,   these  observations  suggest   that  1,25(OH)2D3   inhibits  cell  cycle  progression  
both   directly   and   indirectly   through   various   target   genes   that   exert   control   over   the   cell  
cycle  in  many  phases  by  a  combination  of  discrete  pathways.  Therefore,  the  molecular  basis  
for   the   growth   inhibition   by   1,25(OH)2D3   is   exerted   through   a   combination   of   pathways,  
which  are,  in  part,  tissue-­‐‑specific.  
2.2.3  1,25(OH)2D3-­‐‑induced  apoptosis  and  differentiation  
An   another   anti-­‐‑cancer   feature   of   1,25(OH)2D3   mediated   physiological   activity   is   the  
induction  of  apoptosis.  1,25(OH)2D3  has  been  observed  to  down-­‐‑regulate  the  anti-­‐‑apoptotic  
proteins  B  cell   lymphoma  2   (Bcl-­‐‑2)  and  Bcl-­‐‑2   like1   (Bcl-­‐‑2L1)   in  breast  and  prostate  cancer  
cell  lines  (37,38).  Both  of  these  closely  related  proteins  are  key  factors  protecting  cells  from  
undergoing  apoptosis.  Thus  down-­‐‑regulation  of  these  proteins  by  1,25(OH)2D3  leads  to  the  
induction   of   apoptosis.   Furthermore,   artificial   overexpression   of   Bcl-­‐‑2   in  LNCaP  prostate  
cancer   cells   prevents   1,25(OH)2D3-­‐‑induced   apoptosis   but   does   not   affect   1,25(OH)2D3-­‐‑
mediated   G1   cell   cycle   arrest   in   the   same   cellular   model   (37).   Accordingly,   1,25(OH)2D3  
induces  Bcl-­‐‑2-­‐‑mediated  apoptosis  in  MCF-­‐‑7  breast  cancer  cells  (38),  where  the  inhibition  of  
the   cell   cycle   and   the   modulation   of   IGF   signaling   by   1,25(OH)2D3   have   already   been  
characterized.  As  discussed  above,  the  overall  effect  of  1,25(OH)2D3  on  cellular  growth  is  a  
combination  of  several  signaling  pathways.  
1,25(OH)2D3   can   also   promote   the   differentiation   of   some   cancer   cells,   such   as   the  
myeloid   leukemia   lines,   U937   and   THP-­‐‑1,   into   macrophages   (24,39).   This   1,25(OH)2D3-­‐‑
mediated  differentiation  changes   certain   forms  of   leukemia   to  a   less  malignant  and  more  
mature  phenotype,   and   is   therefore   considered   as   a   potential   therapeutic   and  preventive  
agent  for  these  cancers  (40).  However,  the  mechanisms  of  differentiation  include  numerous  
targets  and  pathways  that  1,25(OH)2D3  may  control.  For  example,  1,25(OH)2D3  is  associated  
with  the  regulation  of  extracellular  signaling  through  cell  surface  pathways,  such  as  Wnt/β-­‐‑
catenin,   Hedgehog,   and   Notch,   which   are   involved   in   cellular   differentiation   (41).   In   a  
study   performed   in   colon   cancer   cells,   1,25(OH)2D3   induced   a   differentiated   phenotype  
through   the   inhibition   of   the   Wnt/β-­‐‑catenin   signaling   pathway   (42).   The   Wnt/β-­‐‑catenin  
signaling   is   repressed   by   1,25(OH)2D3   via   several   mechanisms   (42,43).   First   of   all,  
1,25(OH)2D3   promotes   direct   VDR-­‐‑β-­‐‑catenin   interaction,   which   inhibits   transcriptionally  
active  β-­‐‑catenin.  Secondly,  1,25(OH)2D3  enhances  nuclear  export  of  β-­‐‑catenin  via  increase  of  
E-­‐‑cadherin.   Thirdly,   1,25(OH)2D3   up-­‐‑regulates   the   potent  Wnt-­‐‑antagonist   gene,   Dickkopf  
WNT   Signaling   Pathway   Inhibitor   1   (DKK-­‐‑1).   Generally,   the   modulation   of   multiple  
complex   extracellular  pathways   involved   in   1,25(OH)2D3-­‐‑mediated  differentiation   is  most  
likely   a   consequence   of   the   regulation   of   primary   and   secondary   target   genes.   Since   the  




principles  of   the  general  mechanism  by  which  1,25(OH)2D3   induces  differentiation  cannot  
been  drawn  yet.  
2.2.4  Immuno-­‐‑modulatory  actions  of  1,25(OH)2D3  
The   involvement   of   vitamin   D3   signaling   in   the   regulation   of   immune   function   is   well  
established.   Several   epidemiological   studies   have   reported   that   a   low   vitamin   D   status  
correlates   with   the   increased   risk   of   developing   autoimmune   diseases,   such   as   type   1  
diabetes,   systemic   lupus   erythematosus,   multiple   sclerosis,   inflammatory   bowel   disease  
and   rheumatoid   arthritis   (44).   Interestingly,   the   study   previously   discussed   above,   that  
analyzed   differentially   expressed   gene   sets   in   whole   blood   mRNA   samples   between  
vitamin  D  deficient  and  sufficient  groups  of  Norwegian  women,  found  that  the  majority  of  
differentially   expressed   gene   sets   between   the   groups   were   related   to   immune   function  
(13).  Those  included  gene  sets  involved  in  innate  immunity  signaling,  cytokine  production,  
chemokine  signaling,  T  cell  receptor  signaling  and  Toll-­‐‑like  receptor  (TLR)  signaling.  Most  
of   these  are  associated  with  vitamin  D  deficiency  supporting   the  causal   role  of  vitamin  D  
deficiency  in  autoimmune  diseases.  
All   central   immune   cells,   such   as   CD4+   and   CD8+   T   cells,   B   cells,   neutrophils,   and  
antigen-­‐‑presenting   cells,   including   monocytes,   macrophages   and   dendritic   cells   express  
VDR   (45,46).   In  addition,  during  CD4+  T   cell   activation,   the   low  basal   expression   level  of  
VDR   is   increased   (46).   Interestingly,   these   cells   also   express   the   25(OH)2D3  metabolizing  
enzyme   CYP27B1,   which   would   permit   local   increases   in   1,25(OH)2D3   levels   without  
affecting   systemic   levels   of   the   hormone.   CYP27B1   expression   is   induced   by   various  
inflammatory   signals   including   interferon-­‐‑γ   (IFN-­‐‑γ),   ligands   for   the  TLR2/1-­‐‑complex  and  
for  TLR4,  and  viral  infections  (44).  Since  1,25(OH)2D3  target  genes  include  various  immune-­‐‑
related   genes,   locally   produced   1,25(OH)2D3   may   act   in   a   similar   fashion   to   locally  
produced   cytokines.   On   the   other   hand,   1,25(OH)2D3   suppresses   the   expression   of   TLR2  
and  TLR4  (47).  TLRs  are  cell  surface  receptors  expressed  in  macrophages  and  dendritic  cells  
and   are   responsible   for   the   recognition   of   foreign   microbes   and   the   activation   of   an  
inflammatory  response.  As  mentioned  above,  CYP27B1  expression  is  induced  by  TLR2  and  
TLR4,  and  therefore  the  down-­‐‑regulation  of  TLRs  by  1,25(OH)2D3  suggests  that  in  addition  
to  the  inhibition  of  TLR-­‐‑mediated  bacterial  response,  CYP27B1-­‐‑mediated  induction  of  local  
1,25(OH)2D3  production  may  function  as  feedback  regulation  for  TLR-­‐‑signaling.  
1,25(OH)2D3   mediates   immuno-­‐‑modulatory   functions   also   through   the   inhibition   of  
nuclear   factor-­‐‑κB   (NF-­‐‑κB)   signaling   in   various   human   cells   (48,49).   NF-­‐‑κB   is   a   widely  
expressed   transcription   factor   regulating   genes   involved   in   immunity,   inflammatory   and  
stress  responses.  While  inactive,  NF-­‐‑κB  is  kept  in  the  cytosol  through  the  interaction  with  
the   protein  NF-­‐‑κB   inhibitor   (IκBα)   that  masks   the   nuclear   localization   signals   of  NF-­‐‑κB.  
During   immune   cell   activation   IκBα   is   phosphorylated,  which   leads   to   subsequent   IκBα  
degradation   and   thereby   making   translocation   of   NF-­‐‑κB   to   the   nucleus   permissible.  
1,25(OH)2D3  increases  IκBα  mRNA  and  protein  levels,  which  reduces  nuclear  translocation  
of   NF-­‐‑κB   and   thus   inhibits   its   activity   (48).   In   contrast,   another   study   suggested   that  
1,25(OH)2D3   indirectly   inhibits   the   DNA   binding   capacity   of   NF-­‐‑κB   (49).   In   general,  
through   NF-­‐‑κB   inhibition,   1,25(OH)2D3   is   able   to   suppress   the   inducibility   of   genes  
encoding  pro-­‐‑inflammatory  cytokines  and  chemokines,  such  as  TNF,  chemokine  CXC  motif  
ligand  8  (CXCL8)  or  interleukin  6  (IL6),  which  are  regulated  by  NF-­‐‑κB.  
In   addition   to   general   immune   suppression   through   NF-­‐‑κB   inhibition,   1,25(OH)2D3  
directly   regulates   the   expression   of   cytokines.   For   example,   1,25(OH)2D3   down-­‐‑regulates  
the  expression  of   the  cytokine  genes   IL10,   IL2  and   IL12B   through  primary  VDR-­‐‑mediated  
regulation  (50,51).  Analysis  in  lipopolysaccharide  (LPS)-­‐‑induced  human  THP-­‐‑1  monocytes  
revealed   that   the   IL10  gene  exhibits  only   short-­‐‑term  primary  down-­‐‑regulation  during   the  
first  8  h  after  1,25(OH)2D3   treatment.  Then  its  expression  returns  to  basal   levels  after  24  h  
(50).  This   is   followed  by  a  delayed   secondary  effect  of   a   3-­‐‑fold  up-­‐‑regulation  of   the  gene  




mechanisms   that   include   the   inhibition   of   i)   the   function   of   macrophages   and   dendritic  
cells,   ii)  monocyte  maturation   and   iii)   cytokine   expression   and   secretion   (52).   Through   a  
transient  down-­‐‑regulation  of  IL10  gene  expression,  1,25(OH)2D3  allows  innate  immunity  to  
function   before   the   delayed   induction   of   the   cytokine   suppresses   the   innate   immune  
response   preventing   chronic   inflammation   (50).   Furthermore,   in   a   study   using   THP-­‐‑1  
monocytes,   which   were   differentiated   into   macrophages   with   phorbol   12-­‐‑myristate  
13-­‐‑acetate   (PMA),   the   IL1B   gene   was   characterized   as   primary   1,25(OH)2D3   target   (53).  
Induction  of   IL1B   expression   in   response   to   1,25(OH)2D3   treatment  was  observed  both   in  
non-­‐‑infected   and   in   mycobacterium   tuberculosis   infected   cells.   Interestingly,   infection  
enhanced  basal  VDR  binding  almost  10-­‐‑fold   to  a   site   located  4.3  kb  upstream  of   the   IL1B  
TSS.  In  response  to  1,25(OH)2D3,  the  chemokine  genes  CCL3,  CCL4,  CCL8,  CXCL8  and  TNF  
were   also   induced   in   both   non-­‐‑infected   and   infected   cells.   However,   the   study   did   not  
determine  whether  those  genes  are  primary  VDR  targets  (53).  Nevertheless,  secretion  of  all  
these  1,25(OH)2D3-­‐‑induced  gene  products  was  observed  only  in  infected  cells.  This  suggests  
that  although  1,25(OH)2D3  promotes  the  transcriptional  up-­‐‑regulation  of  cytokines,  it  does  
not   induce   unwanted   inflammation   in   resting   cells.   In   a   study   performed  with   primary  
monocytes  derived  from  healthy  controls  or  from  patients  with  type  1  and  type  2  diabetes,  
treatment  with  IFN-­‐‑γ  induced  the  mRNA  expression  of  the  cytokines  IL6,  TNF,  IL1  and  the  
chemokine  CXCL8  in  all  three  sources  of  cells  (54).  The  induction  was  most  pronounced  in  
monocytes  isolated  from  type  2  diabetes  patients  and  only  in  the  latter  samples  1,25(OH)2D3  
could  significantly  reduce  the   inducibility  of   the  genes   in  response  to  IFN-­‐‑γ  treatment.   In  
contrast,  no  effects  were  observed  in  cells  from  healthy  donors  or  type  1  diabetes  patients.  
This  suggests  that  1,25(OH)2D3  is  involved  in  the  inhibition  of  the  pro-­‐‑inflammatory  profile  
observed  in  type  2  diabetes  patients,  and  may  therefore  have  protective  role  in  controlling  
type  2  diabetes  progression  as  well.  
2.2.5  1,25(OH)2D3  in  adipose  tissue  
Vitamin  D3   is   stored   in   human   adipose   tissue.   Interestingly,   obesity   and   vitamin  D  
deficiency  are  known  to  associate  with  each  other.  A  large  meta-­‐‑analysis  of  21  adult  cohorts  
with   42,024  participants   analyzed   the   causality   of   the   vitamin  D   status   and   a   high   body-­‐‑
mass-­‐‑index  (BMI)  (55).  By  using  a  Mendelian  randomization  approach,  the  study  revealed  
that   a   high   BMI   is   the   reason   for   a   lower   systemic   vitamin  D   status.   In   accordance,  
individuals   who   are   obese   may   require   a   two   to   three   times   higher   dose   of   vitamin  D3  
supplementation,   in   order   to   maintain   the   same   25(OH)D3   levels   than   individuals   with  
normal   weight   (9).   The   observation   of   a   low   vitamin  D   status   in   obesity   suggests   that  
vitamin  D   deficiency  may   have   a   role   in   the   adverse   health   effects   originally   associated  
with  obesity.  However,  which  are  underlying  mechanisms  that   lead  to  the  suppression  of  
vitamin  D   levels   in   individuals  who   are   obese,   is   still   under   debate.   It   is   suggested   that  
obesity   reduces   the   bioavailability   of   vitamin  D3,   since   orally   supplied   vitamin  D   is  
sequestrated   in  visceral   fat,  while  subcutaneous  fat  stores  vitamin  D3  after   its  synthesis   in  
the   skin   (56).  Another   study   suggests   that   large   volumetric   dilution   in   obese   individuals  
explains  the  low  vitamin  D  availability  (57).  
Human  adipose  tissue  is  not  only  a  storage  site  for  vitamin  D3  but  adipose  cells  express  
VDR   and   are   subject   to   1,25(OH)2D3-­‐‑dependent   gene   regulation.   A   microarray   study  
performed  with  adipocytes  derived  from  subcutaneous  fat  revealed  that  237  genes  respond  
to  1,25(OH)2D3.  These  genes  were  largely  related  to  inflammation  and  oxidative  stress  (58).  
However,   the   lack   of   genome-­‐‑wide   VDR   binding   data   in   adipocytes   does   not   allow   an  
evaluation   how   many   of   the   responding   genes   may   be   primary   1,25(OH)2D3   targets.  
Furthermore,   microarray   studies   that   used   human   Simpson-­‐‑Golabi-­‐‑Behmel   syndrome  
(SGBS)  adipocytes,  which  had  been  treated  with  medium  derived  from  PMA-­‐‑differentiated  
U937  macrophages,  indicated  an  impact  of  macrophage  signaling  on  the  vitamin  D3  system  
in  adipocytes   (59).  This   interesting  approach   revealed  a  high   inducibility  of   the  CYP27B1  




macrophage-­‐‑conditioned   medium.   Although   the   factors   which   up-­‐‑regulate   CYP27B1  
expression   are   unknown,   the   observation   is   similar   to   that   in   monocytes/macrophages,  
where  CYP27B1   expression   is   strongly  up-­‐‑regulated   in   response   to  various   inflammatory  
signals   (44).   The   increase   in  CYP27B1   mRNA   expression   suggests   that   during   infection,  
adipose   tissue   functions   as   a   site   for   local   1,25(OH)2D3   production.   Interestingly,  
macrophage-­‐‑conditioned   medium   also   increases   VDR   protein   expression   after   24   h   of  
treatment  (59).  This  suggests  that  macrophage  signaling  promotes  intracellular  1,25(OH)2D3  
regulation,  and  not  only  the  production  of  the  hormone.  
1,25(OH)2D3  regulates  the  expression  of  several  cytokines  in  adipocytes.  In  a  study  that  
used   primary   subcutaneous   adipose   tissue   cells   and   adipocytes   differentiated   from   bone  
marrow-­‐‑derived   human   mesenchymal   stromal   cells,   co-­‐‑treatment   with   1,25(OH)2D3   and  
LPS  reduced  the  ability  of  LPS  to  induce  IL6  secretion  (60).  In  addition,  pre-­‐‑treatment  with  
1,25(OH)2D3  for  24  h  sequestered  LPS-­‐‑mediated  inducibility  of  mRNA  and  protein  secretion  
of  IL6.  It  was  shown  that  in  both  cell  types  1,25(OH)2D3  inhibited  NF-­‐‑κB  translocation  to  the  
nucleus   by   increasing   IκBα   availability.   Thus,   pre-­‐‑treatment   with   1,25(OH)2D3   blocks  
NF-­‐‑κB   inducibility   and   prevents   LPS   to   induce   IL6.  Another   study   reported   that   in   pre-­‐‑
adipocytes   derived   from   subcutaneous   adipose   tissue,   1,25(OH)2D3   reduced   the   basal  
secretion  of  CCL2,  CXCL8  and  IL6  (61).  Similarly,  as  in  the  previous  study,  these  reductions  
in   cytokine   expression   were   associated   with   1,25(OH)2D3-­‐‑mediated   induction   of   IκBα.  
Interestingly,  basal  secretion  of  CCL2,  CXCL8  and  IL6  was  strongly  reduced  when  the  pre-­‐‑
adipocytes  were  differentiated  into  mature  adipocytes.   In  a  study  performed  with  human  
SGBS  pre-­‐‑adipocytes,  the  expression  levels  of  all  48  human  NRs  were  analyzed  during  the  
differentiation  process  from  pre-­‐‑adipocytes  to  adipocytes  (62).  It  was  found  that  15  of  the  30  
expressed   NRs,   including   VDR,   are   significantly   down-­‐‑regulated   during   differentiation,  
while  only  six  NR  genes  had  increased  mRNA  expression.  This  suggests  that  1,25(OH)2D3  
may  have  a  more  profound  effect  in  pre-­‐‑adipocytes  compared  to  mature  adipocytes.  
In   summary,   adipocytes   exhibit   active  1,25(OH)2D3   signaling  and  have   the  potential   to  
synthesize   1,25(OH)2D3   locally.   The   observed   reduction   in   inflammation   via   a   down-­‐‑
regulation   of   cytokines   resembles   that   of   immune   cells.   However,   due   to   the   lack   of  
genome-­‐‑wide   VDR   binding   data,   little   is   known   about   the   global   primary   response   to  
1,25(OH)2D3  in  adipocytes.  
2.3 VITAMIN D RECEPTOR 
1,25(OH)2D3  mediates  all  of  its  biologically  relevant  functions  through  the  activation  of  the  
transcription  factor  VDR.  VDR  is  a  member  of  NR  superfamily   that  consists  of  48   ligand-­‐‑
activated,  DNA  binding  receptors,  which  are  important  regulators  of  gene  expression  (63).  
Regulation  of  gene  expression  by  NRs  mediates  immediate  transcriptional  response  of  their  
ligands,  such  as  dietary  lipids,  vitamin  A  and  D,  steroid  and  thyroid  hormones.  Therefore,  
NRs   are   important   ligand-­‐‑inducible   switches   during   cellular   metabolism,   growth   and  
differentiation.   Since   1,25(OH)2D3   is   the   only   natural   high   affinity   ligand   for   VDR,   the  
physiological  consequence  of  1,25(OH)2D3  signaling  is  mostly,  if  not  solely,  the  outcome  of  
VDR   action.  Moreover,   VDR   is  widely   expressed,   and   therefore  most   human   tissues   are  
responsive  to  1,25(OH)2D3  (64).  
Like  most  other  NRs,  the  VDR  protein  is  composed  of  a  non-­‐‑conserved  amino-­‐‑terminal  
domain,   followed   by   a   highly   conserved   DNA-­‐‑binding   domain   (DBD),   a   non-­‐‑conserved  
hinge  domain  and  a  structurally  conserved  carboxy-­‐‑terminal  ligand-­‐‑binding  domain  (LBD)  
(65).  The  DBD  contains  two  tandem  zinc  finger  motifs  that  mediate  sequence-­‐‑specific  DNA  
binding.  The  DBD  and  the  LBD  are  connected  by  the  hinge  region,  whose  flexibility  allows  
the  DBD  to  efficiently  bind  DNA  in  various  receptor  conformations.  The  VDR  hinge  region  
also  harbors  a  nuclear  localization  signal.  In  addition,  the  hinge  region  stabilizes  the  DBD-­‐‑




LBD  contains  a  ligand-­‐‑binding  pocket  (LBP),  which  allows  specific  ligand  recognition.  The  
inner   surface   of   the   LBP   is   formed   of   some   40   non-­‐‑polar   amino   acid   residues   and   three  
pairs  of  polar  anchoring  points  that  explain  the  high  specificity  of  LBP  toward  its  respective  
ligand   (63).   However,   the   volume   of   the   LBP   varies   significantly   between   NRs   being  
between  400  and  1400  Å3.  
In   addition   to   ligand-­‐‑binding   properties,   the   LBD   mediates   associations   with   other  
transcription   factors   and   co-­‐‑regulatory   proteins   (67).   For   more   details   see   the   following  
chapter.  
2.3.1  Mechanism  of  1,25(OH)2D3  target  gene  regulation  by  VDR  
1,25(OH)2D3   is   a   small   lipophilic   molecule   that   can   directly   activate   VDR-­‐‑mediated  
transcription   in   the   nucleus.  Gene   regulation   by   systemic,   extracellular   1,25(OH)2D3   does  
not  require  additional  signal  transduction  steps.  When  1,25(OH)2D3  docks  into  VDR’s  LBP,  
a  conformational  change  on  the  surface  of  the  LBD  occurs,  which  in  turn,  alters  the  protein-­‐‑
protein  interaction  profile  of  the  receptor  (63).  Thus,  1,25(OH)2D3  triggers  the  interaction  of  
DNA-­‐‑bound   VDR   with   other   transcription   factors   and   with   the   basal   transcriptional  
machinery.  This  allows  the  receptor  to  directly  modulate  the  expression  of  its  target  genes.  
In   order   to   form   a   stable   VDR-­‐‑DNA   complex,   VDR   requires   complex   formation   with  
another  DNA-­‐‑binding  partner  protein.  Ligand-­‐‑activated  VDR  interacts  preferentially  with  
the  retinoid  X  receptor  (RXR),  i.e.  it  forms  a  heterodimer.  The  DBDs  of  VDR  and  RXR  both  
recognize  the  hexameric  DNA  consensus  sequence  RGKTSA  (R  =  A  or  G,  K  =  G  or  T,  S  =  C  
or  G)  and  due  to  steric  constrains  of   the  VDR-­‐‑RXR  complex,   the  optimal  binding  motif   is  
formed  by  a  direct  repeat  of  two  core  binding  sequences  spaced  by  three  nucleotides  (DR3)  
(68,69).   However,   genome-­‐‑wide   VDR   binding   site   analyses   have   indicated   that   only   the  
minority   of   all   VDR   loci   contains   the   classical   DR3-­‐‑type   binding   motif.   This   is   further  
discussed  in  the  next  chapter.  
Even  in  the  absence  of  ligand,  VDR  is  able  to  bind  to  DNA,  although  in  this  case  the  VDR  
pool   is  spread  between  cytoplasm  and  nucleus.  1,25(OH)2D3  stimulation  promotes  greater  
nuclear   localization   of   the   receptor,   its   dimerization   with   RXR   and   subsequent   DNA  
binding   (70).   Similarly,   analyses  of  genome-­‐‑wide  VDR  binding   sites  have   shown   that   the  
number  of  occupied  VDR  binding  sites  in  the  human  genome  increases  in  response  to  VDR  
ligand  stimulation  (71).  When  VDR  is  bound  to  DNA  in  the  absence  of  ligand,  the  receptor  
associates   with   co-­‐‑repressors,   such   as   NCoR,   SMRT   and   Cops2   (also   known   as   Alien)  
(72,73).  Co-­‐‑repressors  mediate  transcriptional  repression  through  a  direct  inhibition  of  the  
transcription  machinery  and  via  the  recruitment  of  repressing  chromatin  modifiers,  such  as  
histone  deacetylases  (HDACs).  During  ligand-­‐‑induced  VDR  activation  the  conformational  
change   on   the   VDR-­‐‑LBD   surface   causes   the   release   of   co-­‐‑repressors   and  HDACs   and   is  
followed  by  the  recruitment  of  co-­‐‑activators.  A  large  number  of  co-­‐‑activators,  including  the  
multi-­‐‑subunit  mediator  complex,  form  a  bridge  between  the  VDR  and  the  TSS  regions  of  its  
target  genes.  This  enables  the  interaction  of  VDR  with  the  basal  transcriptional  machinery  
containing  RNA  polymerase  II,  leading  to  the  initiation  of  gene  transcription  (74,75).  
Although   the   initiation   of   mRNA   synthesis   by   1,25(OH)2D3   is   caused   through   the  
interaction   of   VDR   with   the   transcriptional   machinery,   the   process   is   not   always  
continuous,   since   cyclical   accumulation  of   some  VDR   target   gene  mRNA   levels  has  been  
observed.  Furthermore,   it  has  been   shown   that   cyclical   induction  of   the  VDR   target  gene  
CDKN1A  mRNA,  in  response  to  1,25(OH)2D3,  results  from  the  cyclical  association  of  VDR  
with  binding   sites  nearby   the  CDKN1A  gene   (76).   In  addition,   expression  of   the   estrogen  
receptor  target  gene  trefoil  factor-­‐‑1  (77)  and  that  of  the  VDR-­‐‑induced  CYP24A1  gene  (78,79)  
are   the   result   of   similar   cyclical   association   of   the   receptor,   RNA   polymerase   II   and   co-­‐‑
factors  with  the  respective  gene  promoters.  
Taken   together,   transcriptional   cycling   is   a   consequence   of   a   dynamic   oscillation   of  




RNA  polymerase  II  complexes,  a  dynamic  regulation  of  transcription  enhances  the  control  
over  the  transcription  process  mediated  by  NRs.  
2.3.2  Genome-­‐‑wide  VDR  locations  
Chromatin   immunoprecipitation   (ChIP)   is   an   experimental   technique   that   is   used   to  
quantify   interactions   between   specific   proteins   and   genomic   DNA.   It   is   often   used   to  
monitor   the   binding   of   transcription   factors   to   their   genomic   targets   or   to   detect   the  
presence   of   specific   histone   modifications.   ChIP   combined   with   massive   parallel   DNA  
sequencing   (ChIP-­‐‑seq)   provides   a   genome-­‐‑wide   view   of   transcription   factor   binding.  
During  this  thesis  project,  VDR  ChIP-­‐‑seq  data  from  undifferentiated  THP-­‐‑1  monocytic  cells  
(81),   LPS-­‐‑differentiated   macrophage-­‐‑like   THP-­‐‑1   cells   (71),   immortalized   lymphoblastoid  
cell  lines  GM10855  and  GM10861  (82),  LX2  hepatic  stellate  cells  (83)  and  LS180  colon  cancer  
cells   (84)   have   been   used.   Since   in   the   original   studies,   different   analysis   software   and  
thresholds  for  peak  determination  were  applied,  the  number  of  peaks  (that  equate  to  VDR  
binding  sites)  was  not  fully  comparable  between  the  datasets.  Therefore  a  harmonized  re-­‐‑
analysis   of   the   original   data   by   using   standardized   protocols  was   recently   performed   in  
order  to  allow  cross  data  set  comparisons  (71).  
The  total  number  of  VDR  binding  locations  increased  in  all  six  cellular  models  after  the  
cells  were   treated  with  VDR   ligand.   The   increase   in   peak   number  was   greatest   in   LS180  
cells,  where  VDR  bound  only  to  165  genomic  regions  in  the  absence  of  ligand,  while  after  
3  h  of  1,25(OH)2D3  treatment  almost  3,800  VDR  binding  sites  were  occupied.  In  contrast,  in  
LX2  cells  20  h   treatment  with  VDR  ligand  kept   the  number  of  VDR  peaks   in   the  order  of  
1,500.  Highest   total  number  of  VDR  peaks  was  observed   in   the   lymphoblastoid   cell   lines  
GM10855  and  GM10861,  with  more  than  6,000  and  12,000  peaks  after  36  h  of  1,25(OH)2D3  
treatment,  respectively.  Similar  to  the   increase   in  VDR  binding  sites   in  response  to   ligand  
treatment,   the   ChIP-­‐‑seq   study   that   used   primary   T   cells   isolated   from   nine   human  
individuals   (12)   showed   that   the   number   of   VDR   peaks,  which   varied   between   200   and  
7,000,   correlates  with   the   serum  25(OH)D  concentration  of   the   individuals.  However,   the  
raw  data   for   this   study   is   not   available   for   further   analysis   and   therefore   the   number   of  
peaks  is  not  directly  comparable  with  that  of  the  harmonized  analysis  (71).  
In  total,  the  six  ChIP-­‐‑seq  datasets  revealed  that  there  are  more  than  20,000  unique  VDR  
binding   sites.   The   actual   number   depends   slightly   on   the   maximum   allowed   distance  
between  the  peak  summits.  Interestingly,  when  allowing  that  the  peak  summits  may  differ  
in  maximum  by  250  bp,  almost  70%  of  the  peaks  are  cell   type  specific,   i.e.   they  are  found  
uniquely  in  one  cell  line  tested.  Importantly,  under  this  condition,  only  55  VDR  binding  loci  
are  conserved  in  all  six  cell  lines  suggesting  that  VDR  signaling  and  the  number  of  genomic  
binding  sites  is  very  cell  type  dependent.  
A   screening   for   transcription   factor   binding   motif   below   the   summits   of   VDR   peaks  
identified  DR3-­‐‑type  sequences  as  the  dominant  VDR  binding  site   in  all  six  cell   types  (71).  
However,   only   some  2,500  of   the  more   than  20,000  VDR  binding   sites   carry   this   classical  
DR3-­‐‑type   motif,   but   the   DR3   occurrence   rate   is   largely   dependent   on   the   cell   type.  
Nevertheless,   the   prevalence   of   DR3-­‐‑type   sequences   correlates   with   the   size   (fold  
enrichment   value)   of   the   VDR   peak.   Prominent   VDR   peaks   represent,   in   general,   strong  
VDR  binding  and  good  quality  of   the  ChIP   signal.  When   the  VDR  peaks  were   sorted  by  
their   fold   enrichment   value,   the   DR3   rate   of   occurrence   in   the   group   of   weakest   VDR  
binding  sites  was  below  20%,  while  in  the  group  of  the  most  prominent  peaks,  the  DR3  rate  
of  manifestation  ranged  between  70  and  90%.  When  all  VDR  sites  are   taken   into  account,  
the   DR3   incidence   rate   in   ligand-­‐‑treated   cells  was   higher   than   in   unstimulated   samples.  
This  suggests  that  many  of  the  non-­‐‑DR3-­‐‑type  VDR  binding  sites  in  unstimulated  cells  may  
function  as  temporary  nuclear  storage  places  for  VDR,  from  where  the  receptor  is  shifted  to  
the   active   DR3-­‐‑type   locations   during   ligand-­‐‑activation.   However,   the   existence   of  
prominent,  non-­‐‑DR3-­‐‑type  VDR  sites  in  all  cell  types  indicates  that  these  types  of  sites  can  




of  these  sites  is  unknown.  However,  it  has  been  suggested  that,  at  these  sites,  VDR  forms  a  
heterodimer  with  a  presently  undefined  DNA  binding  partner  or  may  complex  with  other  
DNA  binding  proteins,  such  as  pioneer  factors,  without  direct  DNA  binding  (74).  
2.3.3  Chromatin  remodeling  in  relation  to  VDR-­‐‑mediated  gene  regulation  
In  order   to   fit   into   the  nucleus,  genomic  DNA   is   tightly  packed  around  histone  octamers  
forming   nucleosomes   (85).   The   nucleosome   fiber   is   further   condensed   into   higher   order  
chromatin  structures.  This  highly  condensed  chromatin  is  transcriptionally  inactive  and  not  
accessible  to  most  transcription  factors.  VDR  belongs  to  the  latter  and  has  to  overcome  the  
repressive  nature  of  condensed  chromatin,  in  order  to  access  its  binding  loci.  As  mentioned  
earlier,   in   the   absence   of   1,25(OH)2D3   VDR   associates   with   HDACs.   This   generates   and  
promotes   condensed   chromatin   structures   by   deacetylating   histones,   which   prevents  
transcriptional   activation   (73).   In   contrast,   some   of   co-­‐‑activators   that   interact   with   VDR  
after   ligand   activation   possess   histone   acetyltransferase   (HAT)   activity.   This   induces  
histone   acetylation,   which   in   turn   opens   condensed   chromatin,   in   order   to   make   it  
accessible   for   other   transcription   factors   (85).   Opening   of   compacted   chromatin   is   a  
prerequisite  for  transcription  factors  to  activate  transcription.  Via  complex  formation  with  
chromatin   modifiers   ligand-­‐‑induced   VDR   mediates   local   chromatin   relaxation   and  
increases  the  accessibility  of  other  factors  involved  in  transcription.  Therefore,  1,25(OH)2D3-­‐‑
induced  chromatin  opening  is  one  hallmark  of  a  prominent  VDR  binding  site.  
Genome-­‐‑wide  rates  of  open  chromatin  can  be  analyzed  by  using  formaldehyde-­‐‑assisted  
isolation   of   regulatory   elements   (FAIRE)   combined   with   massive   parallel   sequencing  
(FAIRE-­‐‑seq).   A   time   course   FAIRE-­‐‑seq   analysis   of   1,25(OH)2D3-­‐‑mediated   chromatin  
opening  in  THP-­‐‑1  monocytes  demonstrated  that  some  87%  of  the  1,000  VDR  binding  sites  
in   these   cells   are   located  on  open   chromatin   (86).   Interestingly,   at   165  VDR  binding   sites  
1,25(OH)2D3   induces   a   strong   increase   of   chromatin   accessibility   within   2  h   after   ligand  
treatment,  66%  of  which  contain  a  DR3-­‐‑type  sequence.  This   is  more  than  double   than  the  
average  DR3  occurrence  rate  in  this  cellular  model.  In  contrast,  from  the  500  VDR  binding  
sites,   whose   chromatin   accessibility   was   unchanged   by   1,25(OH)2D3   treatment,   only   less  
than  20%  have  a  DR3-­‐‑type  sequence  residing  below  the  VDR  peak  summit.  
Taken   together,   genome-­‐‑wide   data   of   dynamic   ligand-­‐‑mediated   chromatin   opening  
emphasize  the  dominant  role  of  DR3-­‐‑type  motifs  as  the  preferred  site  for  VDR  binding.  A  
DR3-­‐‑type   site,   together   with   ligand-­‐‑inducible   chromatin   opening,   is   therefore   a   good  
indicator  for  the  regulation  of  a  primary  VDR  target  gene  in  the  relative  vicinity  of  the  site.  
2.4 CENTRAL 1,25(OH)2D3 TARGET GENES 
2.4.1  The  IGFBP3  gene  
The  IGFBP3  gene,  a  member  of  IGFBP  gene  family,  is  located  on  chromosome  7  next  to  the  
IGFBP1   gene   and   encodes   a   secreted   protein   of   291   amino   acids   in   size.   There   are   six  
members   in   the   IGFBP  protein   family   that   bind   IGFs  with  high   affinity,   IGFBP1   through  
IGFBP6.   The   IGFBP3   protein   is   the   most   abundant   member   of   the   protein   family   (87).  
IGFBPs  are  important  modulators  of  the  IGF  system,  which  consists  of  IGF-­‐‑I  and  IGF-­‐‑II  and  
their  cell  surface  receptors  IGF-­‐‑IR,  IGF-­‐‑IIR,  as  well  as  the  insulin  receptor  (88).  IGF-­‐‑I  and  -­‐‑II  
are   important   mitogens   promoting   cellular   growth   and   metabolism   of   normal   and  
malignant  cells.  IGFs  are  produced  mainly  by  the  liver  in  response  to  growth  hormone  and  
mediate   their  mitogenic   effects   primarily   through   activating   IGF-­‐‑IR   (35).  Normally,   IGFs  
are  bound  almost  exclusively  to  IGFBPs,  and  since  IGFBP3  is  the  most  abundant  IGFBP  in  
circulation,  it  represents  the  major  IGF  binding  capacity  in  serum  (35,87).  Additionally,  the  
affinity  of  IGFBP3  for  IGFs  is  higher  than  their  affinity  to  the  membrane  bound  receptors.  




action  (89).  In  addition,  IGFBP3  proteins  exhibit  a  tissue-­‐‑specific  expression  pattern  and  are  
therefore  able  to  regulate  IGF-­‐‑mediated  growth  control  locally.  
Due  to  the  central  role  of  IGFBP3  in  the  regulation  of  IGF-­‐‑induced  cellular  growth,   the  
transcriptional  regulation  of  the  IGFBP3  gene,  such  as  its  up-­‐‑regulation  by  1,25(OH)2D3  or  
its  synthetic  analogs,  controls  also  the  activity  of  IGFs.  This  explains  the  anti-­‐‑cancer  effects  
of  IGFBP3  (34,90).  Furthermore,  IGFBP3  has  been  shown  to  regulate  cellular  growth  also  in  
an   IGF-­‐‑independent   fashion.   IGFBP3   was   suggested   to   translocate   to   the   nucleus   and  
directly   regulate   target   gene   expression   by   forming   a   heterodimer   with   RXR   (91).  
Moreover,  when  not  bound  with  IGFs,   IGFBP3  can  activate  cell  surface  receptors,  such  as  
transforming  growth  factor-­‐‑β  (TGF-­‐‑β)  receptor,  or  induce  caspase-­‐‑mediated  apoptosis  (35).  
The   important  role  of   IGFBP3   in  1,25(OH)2D3-­‐‑mediated  regulation  of  cellular  growth   is  
well   established.   Growth   inhibition   of   MCF-­‐‑7   and   Hs578T   human   breast   cancer   cells  
mediated  by  1,25(OH)2D3  analogs   is  associated  with   increased  IGFBP3  production  (90).   In  
addition,   in   a   study   performed   in   LNCaP   prostate   cancer   cells,   1,25(OH)2D3-­‐‑mediated  
growth   inhibition   showed   to   be   dependent   on   IGFBP3   (92).   The   inhibition   of   cellular  
growth   mediated   by   the   hormone   was   abolished   when   1,25(OH)2D3-­‐‑induced   IGFBP3  
expression   was   withdrawn   using   anti-­‐‑sense   oligonucleotides   against   IGFBP3.   This  
1,25(OH)2D3/IGFBP3-­‐‑mediated   growth   inhibition   was   further   associated   with   increased  
amounts   of   p21   protein,   which   had   been   induced   by   IGFBP3.   Since   the   gene  CDKN1A,  
encoding   p21,   has   been   also   characterized   as   primary   1,25(OH)2D3   target   gene   (25)  
suggesting  that  1,25(OH)2D3  may  target  the  gene  both  directly  as  a  result  of  hormone  action  
and  indirectly  via  IGFBP3  mediated  events.  
In   a   recent   study,   MCF-­‐‑7   breast   cancer   cells   were   used   along   with   MCF-­‐‑7/VDR   cells,  
which   are   resistant   to   both   the   growth   inhibitory   and   the   apoptosis   inducing   signals   of  
1,25(OH)2D3  (34).  The  use  of  these  cellular  models  demonstrated  that  the  impaired  secretion  
of  IGFBP3  protein  was  associated  with  the  inability  of  1,25(OH)2D3  to  inhibit  the  growth  of  
vitamin  D   resistant   MCF-­‐‑7/VDR   cells.   The   study   provided   additional   evidence   that   the  
IGFBP3  gene  has  a  central  role  in  1,25(OH)2D3-­‐‑mediated  growth  inhibition  in  human  breast  
cancer   cells.   Furthermore,   the   regulation   of   the   IGFBP3   gene   by   1,25(OH)2D3   has   been  
studied  in  the  prostate  cancer  cell  lines  LNCaP  and  PC-­‐‑3  and  in  the  osteosarcoma  cell  line  
SaOS-­‐‑2   (36,93).   In   these   studies,   two   functional   VDR   binding   regions   were   shown   to  
mediate  the  primary  response  of  the  IGFBP3  gene  to  1,25(OH)2D3.  
In  summary,  all  these  observations  support  the  view  that  the  primary  1,25(OH)2D3  target  
gene,  IGFBP3,  is  an  important  regulator  of  cellular  growth  and  apoptosis.  
2.4.2  The  G0/G1  switch  2  (G0S2)  gene  
The   G0S2   gene   is   located   on   chromosome   1   and   encodes   a   small   103   amino   acid   long  
protein.  Initially,  the  protein  was  associated  with  the  transition  of  the  cell  cycle  of  cultured  
mononuclear  cells  from  G0  to  G1  phase  (94).  However,  since  then  a  variety  of  functions  for  
G0S2  have  been  described,  such  as  the  ability  to  reduce  the  growth  of  leukemia  cells  (95).  
The  involvement  of  G0S2  in  proliferation,  carcinogenesis  and  metabolism  makes  it  a  multi-­‐‑
functional   protein   (96).   The  G0S2   gene   exists   only   in   vertebrates   but   is   highly   conserved  
between   species,   such   as   a   78%  homology  between  human  and  mouse.   In   the   cytoplasm  
G0S2   is   anchored   to   the   membranes   of   the   endoplasmic   reticulum   and   mitochondria  
(97,98).  
The   1,25(OH)2D3-­‐‑mediated   regulation   of   G0S2   was   long   time   overlooked,   but   in  
microarray  expression  studies  the  gene  was  found  to  be  1,25(OH)2D3  responsive  in  breast,  
colon   and   squamous   cell   carcinoma   cell   lines   (99).   In   addition,   in   a   study   that   used   two  
different  prostate-­‐‑derived  cell   lines,  the  G0S2  gene  was  up-­‐‑regulated  in  RWPE-­‐‑1  cells  that  
are  responsive  to  anti-­‐‑proliferative  actions  of  1,25(OH)2D3,  whereas  it  was  down-­‐‑regulated  
in  PC-­‐‑3   cancer   cells   that   are   insensitive   to   1,25(OH)2D3-­‐‑mediated  growth   inhibition   (100).  
The  G0S2   gene   is   also   regulated   by   peroxisome   proliferator-­‐‑activated   receptors   (PPARs),  




mouse   3T3-­‐‑L1   pre-­‐‑adipocytes   (98).   Interestingly,   increased   G0S2   expression   is   observed  
during   growth   arrest   of   3T3-­‐‑L1   cells,   which   is   an   essential   step   in   their   initiation   of  
differentiation   into   adipocytes.   These   observations   suggest   that   G0S2   is   associated   with  
adipogenesis  via  its  involvement  in  growth  arrest.  
In   hematopoietic   stem   cells   G0S2   inhibits   proliferation   and   promotes   them   into   a  
quiescent   state   through   a   direct   interaction   with   nucleolin   (97).   Nucleolin   is   a   multi-­‐‑
functional  protein   that  promotes  cellular  growth  by  regulating  ribosomal  RNA  and  DNA  
metabolism  in  the  nucleus.  Increased  cellular  levels  of  G0S2  reduce  nucleolin  availability  in  
the  nucleus  by  direct  sequestration  in  the  cytosol,  which  eventually  leads  to  the  inhibition  
of   stem   cell   proliferation.   The   role   of   nucleolin   in   promoting   stem   cell   proliferation   is  
supported   by   observations   that   show   that   nucleolin   expression   is   increased   in   rapidly  
dividing  normal  and  cancer  cells  (101).  
Suppressed   G0S2   expression,   caused   by   hypermethylation   of   its   gene   promoter,   is  
observed   in   cancer   cell   lines   and   tumor   samples   (96).   This   suggests   that   functional  G0S2  
protein  has  a  role   in  the  prevention  of  carcinogenesis.  Moreover,   the  protein  may  act  as  a  
tumor   suppressor,   since   methylation   of   the   G0S2   promoter   leads   to   malignant  
transformation.   Moreover,   in   a   recent   study   the   suppression   of   the  G0S2   gene   in   K562  
human  myeloid   leukemia  cells  was  associated  with  methylation  of   its  proximal  promoter  
and  exon  1   (95).  When  G0S2   expression  was  restored  either  by  demethylation  or  by  gene  
expression  brought  by  viral  transduction,  cellular  proliferation  was  reduced.  Furthermore,  
in   a   nude  mouse   xenograft  model   for   chronic  myeloid   leukemia   tumor   growth   could   be  
significantly  inhibited  by  G0S2  overexpression.  In  summary,  all  these  findings  support  the  
idea  that  the  G0S2  gene  is  a  tumor  suppressor  in  hematopoietic  cells.  
The   ability   of   G0S2   to   inhibit   hematopoietic   stem   cell   proliferation   suggests   that  
sufficiently   expressed   G0S2   may   participate   both   in   inhibiting   carcinogenesis   and   in  
suppressing   tumor  growth   in   the  whole  hematopoietic   system.  Although  G0S2  may  have  
largely   tissue-­‐‑specific   functions,   its   significant   role   as   a   tumor   suppressor   in   human  
leukemia   cells   offers   a   great   therapeutic   potential   in   the   development   of   new   leukemia  
therapeutics.  Since  the  gene  is  suppressed  in  leukemic  cells,  especially  the  mechanisms  for  
recovering  its  functional  expression  should  be  focused  upon.  
2.4.3  The  CDKN1A  gene  
The  CDKN1A  gene  is  located  on  chromosome  6  and  encodes  the  well-­‐‑known  CDKI  protein  
p21.  The  gene  was  identified  originally  as  a  mediator  for  the  tumor  suppressor  protein  p53-­‐‑
induced   cell   cycle   arrest   in   response   to   DNA   damage   (102).  When   induced   by   p53,   p21  
promotes   cell   cycle   arrest   by   directly   interacting   with   both   cyclins   and   CDKs.   This  
efficiently  prevents  the  formation  of  functional  cyclin-­‐‑CDK  dimers  and  leads  to  a  G1  phase  
cell  cycle  block  (23).  In  addition,  small  interfering  RNA  (siRNA)  silencing  of  CDKN1A  gene  
expression   in   LNCaP   prostate   cancer   cells   abolished   growth   inhibition   mediated   by  
1,25(OH)2D3   (103).   This   suggest   that,   at   least   in   this   cell   line,   p21   is   responsible   for  
mediating  the  majority  of  the  anti-­‐‑proliferative  actions  of  1,25(OH)2D3.  Interestingly,  lower  
intracellular  p21  levels  are  suggested  to  promote  cyclin-­‐‑CDK  assembly  and  continuation  of  
the  cell  cycle,  since  normal  physiological  levels  of  p21  have  been  shown  to  be  required  for  a  
fully   functional   cyclin-­‐‑CDK   system   (104).   Thus,   p21   has   a   dual   role   in   cell   cycle   control:  
normal   levels  are   required   for  cell   cycle  progression,  whilst  elevated   levels  of   the  protein  
lead  to  cell  cycle  arrest.  Independent  of  the  cyclin-­‐‑CDK  system,  p21  inhibits  DNA  synthesis  
during   the   S  phase   of   the   cell   cycle   through   PCNA   (proliferating   cell   nuclear   antigen,   a  
processivity   factor   for   DNA   polymerase   δ),   which   controls   the   rate   of   DNA   synthesis  
during  DNA  replication   (105).  Through  a  direct   interaction  with  PCNA,  p21  blocks  other  
DNA  replication  factors  from  binding  to  PCNA,  and  this  results  in  the  inhibition  of  DNA  
replication.  Interestingly,  Myc  protein,  encoded  by  the  gene  v-­‐‑myc  avian  myelocytomatosis  
viral   oncogene   homolog   (MYC),   interacts   with   the   same   domain   of   p21   as   PCNA   (106).  




In   addition   to   its   fundamental   role   in   cell   cycle   regulation,   p21   is   associated   with  
apoptosis  and  differentiation.  The  p53-­‐‑mediated  induction  of  p21  leads  to  cell  cycle  arrest,  
which   also   protects   cells   from   direct   p53-­‐‑mediated   apoptosis.   In   addition,   in   a   study  
performed   in   lung   carcinoma   cells,   p53-­‐‑induced   p21   inhibited   the   function   of   caspase-­‐‑2,  
which,   in   turn,   repressed   apoptosis   initiation   (107).   Moreover,   in   hepatoma   cells  
committing   caspase-­‐‑mediated   apoptosis   p21   protein   is   cleaved   by   activated   caspase-­‐‑3,  
while   in   cells   overexpressing   p21   caspase-­‐‑3-­‐‑mediated   apoptosis   is   suppressed   (108).   The  
observations  that  p21  protects  against  apoptosis  and  promotes  cell  cycle  arrest  suggest  that  
it  is  involved  in  the  decision,  whether  cells  commit  apoptosis  or  enter  cell  cycle  arrest.  Since  
cell  cycle  arrest  is  required  for  terminal  differentiation,  p21  is  able  to  induce  differentiation  
of  both  malignant  and  non-­‐‑malignant  cells  (23).  For  example,  p21  facilitates  differentiation  
of  U937  human  myelomonocytic  cells  (24).  Although  p21  has  an  important  role  in  induced  
differentiation,   in   p21   knockout  mice,   normal   differentiation   of   epidermal   cells   has   been  
observed.  This  suggests  that  under  normal  physiological  conditions  p21  is  not  essential  for  
the  differentiation  process  (109).  
Repression  of  the  CDKN1A  gene  by  mutations  is  very  rare  in  human  cancers.  However,  
CDKN1A  deficient  mice  are  more  prone  to  develop  cancers  upon  exposure  to  γ-­‐‑irradiation.  
Moreover,  CDKN1A  null  mice  show  an   increased  trend  of   tumor  metastasis,  suggesting  a  
role   of   CDKN1A   in   cancer   prevention   (110).   Elevated   cytoplasmic   expression   levels   of  
CDKN1A  have  been  associated  with  the  progression  of  various  cancers  (111)  indicating  its  
role   in   carcinogenesis.   Furthermore,   oncogene   proteins,   such   as   HER-­‐‑2/neu,   are   able   to  
retain   p21   in   the   cytoplasm   and   thereby   prevent   p21-­‐‑induced   growth   arrest   (112).  
Therefore,  altering  the  subcellular  location  of  p21  is  one  important  aspect  when  evaluating  
the  therapeutic  potential  of  p21.  
CDKN1A  was  characterized   first   in  U937  cells  as  up-­‐‑regulated  1,25(OH)2D3   target  gene  
being  regulated  via  a  VDR  binding  site  close   its  TSS   (24).   In  MCF-­‐‑7  cells   the  screening  of  
7  kb  of  the  CDKN1A  promoter  revealed  three  additional  VDR  binding  sites  (76).  However,  
the  VDR  binding  site  described  in  U937  cells  was  not  confirmed  in  MCF-­‐‑7  cells,  suggesting  
a   cell-­‐‑specific   regulation   of   the   gene.   In   addition,   the   gene   is   up-­‐‑regulated   indirectly   by  
1,25(OH)2D3   via   IGFBP3   or   TGF-­‐‑β   dependent   mechanisms   (26,92).   Therefore,   the  
transcriptional  regulation  of  the  CDKN1A  gene  and  the  functionality  of  its  protein  product  
p21  in  growth  inhibition  should  be  evaluated  in  a  tissue-­‐‑  and  cell-­‐‑specific  manner.  
2.4.4  The  MYC  gene  
The  proto-­‐‑oncogene  MYC  is  located  on  chromosome  8  and  encodes  the  transcription  factor  
Myc,  which   is  a   critical   regulator  of   cellular  growth.  The  gene   is  one  of   the  most   studied  
targets   for   cancer   therapy,   since   it   is   dys-­‐‑regulated   in   the   majority   of   cancers   and   its  
inhibition   is   associated   with   reduced   cellular   growth.   The   MYC   gene   is   ubiquitously  
expressed   and   Myc   protein   participates   in   normal   gene   regulation,   primarily   as   a  
heterodimer  with  Myc-­‐‑associated   factor-­‐‑X   (Max)   (113).  Myc   is   an   important   regulator   of  
gene  expression  and  has  global  effects  on  the  human  transcriptome.  It  has  been  estimated  
that  Myc  regulates  some  15%  of  all  human  genes  (114,115).  The  observed  proportion  of  the  
genes   involving  Myc   in   their   regulation   is   even  higher   among  actively   transcribed  genes  
(116).  Moreover,   ChIP-­‐‑seq   analyses   have   shown   that  Myc   has   several   thousand   genomic  
binding   sites,   not   all   of   which   contain   the   traditional   binding   motif   (117,118).   The  
evaluation  of  genomic  Myc  binding  sites  in  the  context  of  microarrays  showed  that  almost  
80%  of  the  Myc-­‐‑dependent  genes  had  an  active  Myc  binding  site  within  1  kb  of  their  TSS  
region  (117).  This  suggests  that  most  of  the  Myc  target  genes  are  under  the  primary  control  
of  the  protein.  In  addition,  Myc  protein  controls  transcriptional  elongation  by  pausing  RNA  
polymerase  II  (116).  Promoter-­‐‑proximal  pausing  (the  regulation  of  transcription  during  the  
elongation   phase   of   transcription),   is   a   widespread   regulatory   mechanism   in   higher  
eukaryotes.   Furthermore,  Myc  has  been   shown   to  modulate  mRNA  cap  methylation   and  




shown   to   initiate  DNA   replication   (119)   and   overexpression   of  MYC   leads   to   increase   in  
replication  origin  activity.  
Dys-­‐‑regulation  or   increased  expression  of   the  MYC  gene   is  observed   in   the  majority  of  
human  cancer  types.  The  gene  is  also  the  most  amplified  oncogene  in  human  cancers.  In  an  
analysis  of  more  than  3,000  tumor  copy  number  profiles,  from  26  cancer  types,  MYC  gene  
chromosomal  amplification  was   found   to  be   the  most   frequent  event,  affecting  14%  of  all  
samples   (120).   The   inhibition   of  Myc   protein   expression   reduces   the   growth   of   cultured  
cells.   Moreover,   in   a   pre-­‐‑clinical   mice   model   for   lung   tumor,   the   suppression   of   Myc  
function  resulted  in  rapid  regression  of  the  tumor  with  increased  apoptosis  (121).  However,  
in   continuously   proliferating   tissues   the   systemic   inhibition   of   MYC   gene   expression  
resulted  in  side  effects:  mice  showed  a  reduction  in  skin  and  hair  growth  and  a  reduced  cell  
proliferation   in   testis  and   intestine,  although  no  apoptosis  was  observed.  This  outcome   is  
however  expected,   since  Myc  has  an  essential   role   in   the  proliferation  of  all  normal  cells.  
Nevertheless,  one  week  after  Myc  inhibition  was  stopped,  all  side  effects  were  reversed  and  
the  mice  showed  a  normal  phenotype.  Therefore,  down-­‐‑regulation  of  the  MYC  expression  
is  of  great  interest  in  the  development  of  new  cancer  therapies.  
It  has  been  already  more  than  30  years  since  the  MYC  gene  was  reported  to  be  a  down-­‐‑
regulated   1,25(OH)2D3   target   (122).   In   the   intervening   years,   MYC   gene   regulation   by  
1,25(OH)2D3   has   been   identified   in   several   cellular   models,   such   as   in   RWPE-­‐‑1   prostate  
cells,  where  MYC  is  a  rapidly  down-­‐‑regulated  primary  1,25(OH)2D3  target  (123).  Therefore,  
the  reported  effects  of  1,25(OH)2D3   in  mediating  growth   inhibition  or   to   induce  apoptosis  
are  most  likely  reflecting  the  cellular  responses  evoked  by  the  down-­‐‑regulation  of  the  MYC  
gene,   to   some   extent.   However,   it   should   be   noted   that   in   cancers,   where  MYC   gene  
amplification  is  common,  not  all  distal  regulatory  elements  of  the  gene  may  be  copied  with  
the  original  gene  and  1,25(OH)2D3  may  not  have  the  same  effect  on  the  regulation  of  MYC.  
In  summary,  Myc  directly  modulates  a  large  number  of  genes  and  pathways,  thus  even  
small   changes   in  MYC   gene   expression  may   have   a   significant   global   impact   on   cellular  
growth.  In  addition,  the  gene  is  associated  strongly  with  the  majority  of  human  cancers  and  
therefore  the  mechanisms  behind  its  primary  regulation  are  of  great  interest.  
2.4.5  The  chemokine  cluster  
Orchestrated  cell   recruitment  and  positioning   is  a  central  event   in   immune  response.  The  
most   important   coordinators   of   leukocyte   trafficking   are   chemokines,   which   are   small  
chemoattractant   cytokines.  The   first   chemokine,  which  was   identified  more   than  25  years  
ago,   is   the   potent   neutrophil   activator   CXCL8,   also   known   as   IL8   (124).   Since   then,  
approximately   50   human   chemokines   and  more   than   20   chemokine   receptors   have   been  
characterized.  The  chemokine  group  is  divided  into  four  families,  C,  CC,  CXC,  and  CX3C,  
based   on   their   cysteine  motifs   (125).   In   the   CC   chemokine   family,   the   first   two   cysteine  
residues  are  next  to  each  other,  in  the  CXC  chemokines  the  cysteine  residues  are  separated  
by   one   amino   acid,   while   within   the   only   characterized   member   of   CX3C   chemokines,  
CX3CL1,   the   cysteine   residues   are   separated   by   three   amino   acids.   In   the   group   of   C  
chemokines,  there  is  only  one  cysteine  residue.  Besides  these  structural  criteria,  chemokines  
can   be   categorized   also   into   functional   groups,   such   as   inflammatory,   homeostatic,   dual-­‐‑
function  and  platelet  chemokines,  but  this  classification  is  not  comprehensive  (125,126).  
Inflammatory  chemokines  are  up-­‐‑regulated  in  response  to  inflammation  and  act  to  direct  
cellular   chemotaxis   towards   the   site   of   inflammation.   Homeostatic   chemokines,   on   the  
other   hand,   are   constantly   expressed   and  participate   in   the   regular   trafficking   as  well   as  
localization   of   lymphocytes   and   dendritic   cells   throughout   the   body   (126).   In   contrast   to  
inflammatory   chemokines,   homeostatic   chemokines   are   relatively   conserved   between  
species  (125).  The  group  of  platelet  chemokines  consists  of  important  regulators  for  platelet  
development  and  maturation.  They  are  associated  with  platelet  activation,  vascular  repair  




Vertebrates   exhibit   significant   differences   in   the   total   number   of   chemokines   (128).  
Humans  and  mice  display  many  differences   in  their   inflammatory  chemokine  profile.  For  
example,   the   CXCL8   gene   exists   only   in   humans.   This   suggests   that   mammalian  
inflammatory   chemokine   genes   are   the   result   of   the   rapid   and   divergent   evolution.  
Moreover,  many  chemokine  genes  are  located  in  chemokine  clusters  spread  throughout  the  
human  genome.  The  CC  chemokine  cluster  on  chromosome  17  comprises  12  genes,  while  
the  CXCL   chemokine  gene   cluster   on   chromosome  4,   spanning  over   350  kb,   contains   the  
nine  genes  CXCL1  to  CXCL8  and  CXCL4.1.  The  members  of  the  latter  chemokine  cluster  are  
classified  as  inflammatory  chemokines  with  the  exception  of  the  platelet  chemokine  CXCL4  
and   its   variant  CXCL4.1   (125).   In   addition,   all   seven   inflammatory   chemokines   carry   an  
angiogenic  Glu-­‐‑Leu-­‐‑Arg  (ELR)  motif  prior  the  first  cysteine  motif  in  their  protein  sequence  
(129).  Chemokines  with   an  ERL  motif   are   the  main   chemoattractants   for  neutrophils   and  
are  able  to  mediate  angiogenesis  (129,130).  Interestingly,  the  ELR  motif  is  not  found  outside  
of   the   CXCL   cluster   and   therefore   the   seven   angiogenic   chemokine   genes   of   the   CXCL  
cluster  form  a  unique  set  of  human  neutrophil  chemoattractants  that  are  able  to  coordinate  
the  connection  between  inflammation  and  angiogenesis.  Although  the  main  function  of  the  
inflammatory   chemokines  of   the  CXCL  cluster   is  neutrophil   chemotaxis   in   inflammation,  
angiogenic  CXC  chemokines  are  also  able  to  promote  cancer  progression  (131).  In  addition,  
elevated   expression   of   angiogenic   chemokines   has   been   associated   with   angiogenesis,  
tumor  growth  and  increased  metastasis.  
Recruitment   of   neutrophils   is   one   the   first   immune   responses   during   infection.  
Therefore,   the  release  of  chemokines   from  the  CXCL  cluster   is   the   first  signal   involved   in  
acute   inflammation.   The   CXCL8   chemokine   is   a   prototypical   member   of   the   CXC  
chemokine   family   and   is   the   most   potent   chemokine   mediating   neutrophil   chemotaxis  
(130).   CXCL8,   and   its   relative   CXCL6,   bind   with   high   affinity   to   the   G-­‐‑protein-­‐‑coupled  
receptors  CXCR1  and  CXCR2,  which  are   found  on   the  surface  of  neutrophils.   In  contrast,  
the   other   CXCL   cluster   chemokines   mediate   their   actions   solely   through   the   CXCR2  
receptor   (130,132).  The  neutrophil   recruitment  activity  of   chemokines   is   regulated   largely  
by   post-­‐‑translational  modifications   (130).   In   addition,   dimerization   of   CXCL8   reduces   its  
receptor  affinity  and  neutrophil  recruitment  potential   (132).  However,  since  inflammatory  
chemokines  are  not  stored  intracellulary,  the  transcriptional  regulation  of  the  CXCL  cluster  
genes   is   also   important   for  CXC  chemokine   function.  For   example,  various   inflammatory  
signals  are  able  to   induce  CXCL8   transcription  via  NF-­‐‑κB-­‐‑mediated  primary  regulation  of  
the  gene  (133).  
In   a   study   that   used   monocytes   from   type   2   diabetes   patients,   cells   having   a   pro-­‐‑
inflammatory   profile   and   high   CXCL8   expression   levels,   co-­‐‑treatment   with   1,25(OH)2D3  
inhibited  IFN-­‐‑γ-­‐‑mediated  induction  of  the  CXCL8  gene  (54).   In  contrast,   in  a  recent  study  
performed   in   PMA-­‐‑differentiated   THP-­‐‑1   macrophages,   1,25(OH)2D3   induced   CXCL8  
expression   more   than   10-­‐‑fold   after   24   h   treatment   (53).   Furthermore,   when   cells   were  
infected   by   mycobacterium   tuberculosis,   which   resulted   in   high   CXCL8   induction,  
1,25(OH)2D3  could  promote  the  transcription  rate  of  CXCL8  even  further.  Consistently  with  
this,   1,25(OH)2D3   treatment   resulted   in   increased   secretion   of   CXCL8   protein   in   infected  
cells.  However,  1,25(OH)2D3  did  not  increase  the  secretion  of  the  CXCL8  protein  in  absence  
of   mycobacterium   infection.   This   suggests   that,   although   1,25(OH)2D3   promotes   the  
transcriptional   regulation   of   the   gene   in   resting   macrophages,   it   is   not   resulting   in  
unwanted  inflammation.  However,  neither  of  these  studies  investigated  whether  CXCL8  is  
primary  target  of  1,25(OH)2D3.  
2.4.6  The  ASAP2  gene  
The  ArfGAP  with  SH3  domain,  ankyrin  repeat  and  PH  domain  2  (ASAP2)  gene  encodes  a  
large   1,006   amino   acids   multi-­‐‑domain   protein   that   is   expressed   in   multiple   tissues.   The  
Asap2   protein   is   composed   of   an   N-­‐‑terminal   α-­‐‑helical   region   with   a   coiled-­‐‑coil   motif,  




activating  protein   (GAP)  domain   containing   a   zink   finger  domain,   an   ankyrin   homology  
region,  a  proline-­‐‑rich  region  and  a  C-­‐‑terminal  Src  homology  3  (SH3)  domain  (134).  Asap2  is  
localized   in   the   Golgi   apparatus   and   at   the   plasma   membrane,   where   it   controls   Arf-­‐‑
mediated   vesicle   budding   and   endocytosis   (134,135).   In   addition,   the   Asap2   protein   is  
involved  in  Fcγ  receptor-­‐‑mediated  phagocytosis  in  macrophages  (136).  
The  ASAP2  gene  may  be  an  additional  factor  in  1,25(OH)2D3-­‐‑mediated  modulation  of  the  
immune   system.   However,   due   to   the   presence   of   multiple   protein-­‐‑protein   interaction  
domains,  not  all  cellular  functions  of  the  Asap2  protein  are  characterized  and  therefore  the  
role  of  1,25(OH)2D3  in  the  regulation  of  such  a  multi-­‐‑functional  gene  may  not  limit  only  to  
immune  function.  
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4  Materials  and  Methods  
4.1 MATERIALS 
4.1.1  Cell  culture  
The   human   non-­‐‑tumorigenic  mammary   epithelial   cell   line  MCF-­‐‑10A,  which  was   used   in  
study   I,   is   a   spontaneously   immortalized   estrogen   receptor   negative   cell   line,  which  was  
derived  from  a  mammary  tissue  of  a  36-­‐‑year-­‐‑old  female  with  cystic  fibrosis  (137).  Adherent  
MCF-­‐‑10A   cells   were   grown   in   a   mixture   of   Dulbecco’s   Modified   Eagle’s   Medium   and  
Ham’s  F12  medium  1:1  (DMEM/F12  (1:1))  supplemented  with  20  ng/ml  epidermal  growth  
factor,   100  ng/ml   cholera   toxin,   10   µμg/ml   insulin,   500   ng/ml   hydrocortisone,   0.1  mg/ml  
streptomycin,   100   U/ml   penicillin   and   5%   horse   serum.   Prior   to   mRNA   and   ChIP  
experiments   the   cells  were   seeded   overnight   in  medium  with   5%   charcoal-­‐‑stripped   fetal  
bovine  serum  (FBS)  instead  of  horse  serum  and  reached  a  density  of  50  to  60%  confluence.  
FBS   had   been   stripped   of   lipophilic   compounds   by   stirring   with   5%   (w/v)   activated  
charcoal   for   3  h   at   room   temperature.  Charcoal  was   then   removed  by   centrifugation  and  
sterile  filtration  (0.2  mm  pore  size).  
The   human   prostate   epithelial   cell   line   RWPE-­‐‑1,  which  was   also   used   in   study   I,   had  
been   derived   from   a   histologically   normal   prostate   of   a   healthy   54-­‐‑year-­‐‑old   male   (138).  
Adherent  RWPE-­‐‑1   cells  were   cultured   in   keratinocyte   serum   free  medium   supplemented  
with  2  mM  L-­‐‑glutamine,  5  ng/ml  human  recombinant  epidermal  growth  factor,  0.05  mg/ml  
bovine  pituitary  extract,  0.1  mg/ml  streptomycin  and  100  U/ml  penicillin.  Prior   to  mRNA  
experiments  the  cells  were  grown  for  72  h  to  reach  a  density  of  45  to  60%  confluence.  
The  human  monocytic  leukemia  cell  line  THP-­‐‑1,  which  as  used  in  studies  II,  III  and  IV,  
was  derived  from  acute  myeloid  leukemia  of  a  one  year  old  male  (139).  Suspension  THP-­‐‑1  
cells   were   grown   in   Roswell   Park   Memorial   Institute   medium   (RPMI)   1640   medium  
supplemented  with   2  mM  L-­‐‑glutamine,   0.1  mg/ml   streptomycin,   100  U/ml   penicillin   and  
10%  FBS.  Prior   to  mRNA  and  ChIP  experiments,  THP-­‐‑1  cells  were   seeded  overnight   in  a  
density   of   500,000   cells/ml   (II,   III)   or   500,000   to   650,000   cells/ml   (IV)   in   phenol   red-­‐‑free  
RPMI   1640   medium   supplemented   with   5%   charcoal-­‐‑stripped   FBS,   2   mM   L-­‐‑glutamine,  
0.1  mg/ml  streptomycin  and  100  U/ml  penicillin.  
Suspension   grown   THP-­‐‑1   monocytes   can   be   differentiated   into   adherent   M2-­‐‑type  
macrophage-­‐‑like   cells   using   PMA   (39).   For   differentiation   THP-­‐‑1   cells   were   seeded   in   a  
density   of   500,000   cells/ml   for   72  h   in   RPMI   1640   medium   supplemented   with   2   mM  
L-­‐‑glutamine,   0.1   mg/ml   streptomycin,   100  U/ml   penicillin,   10%   FBS   and   20   nM   PMA.  
During  mRNA  and  ChIP  experiments,  non-­‐‑differentiated  (non-­‐‑adherent)  cells  were  washed  
off  with  phosphate-­‐‑buffered  saline  (PBS).  
The  human  pre-­‐‑adipocyte   cell   line  SGBS,  which  as  used   in   study  V,  had  been  derived  
from  an  adipose  tissue  specimen  of  a  male  infant  with  Simpson-­‐‑Golabi-­‐‑Behmel  syndrome  
(140).   Adherent   SGBS   cells   were   grown   in   DMEM/F12   (1:1)   supplemented  with   8  µμg/ml  
biotin,   4   µμg/ml   pantothenate,   2   mM   L-­‐‑glutamine,   0.1   mg/ml   streptomycin,   100  U/ml  
penicillin   and   10%   FBS.   All   cell   culture   flasks   or   plates   were   coated   with   a   solution   of  
10  µμg/ml  fibronectin  and  500  µμg/ml  gelatin  in  PBS.  Prior  to  mRNA  and  ChIP  experiments,  
cells   were   seeded   overnight   in   phenol   red-­‐‑free   DMEM/F12   (1:1)   supplemented   with   5%  
charcoal-­‐‑stripped  FBS,  8  µμg/ml  biotin,  4  µμg/ml  pantothenate,  2  mM  L-­‐‑glutamine,  0.1  mg/ml  
streptomycin  and  100  U/ml  penicillin.  
All   cells  were  grown   in  a  humidified  95%  air   /  5%  CO2   incubator  at  37   °C.  During   the  
experiments,   the   cells   were   treated   with   1,25(OH)2D3   (10   nM   final   concentration   diluted  
with  0.001%  ethanol   (I,   II,   III  and   IV-­‐‑PMA  cells),  100  nM  final   concentration  diluted  with  




(V)),   Gemini   (10   nM   final   concentration   diluted  with   0.001%   ethanol)   or   solvent   (0.001%  
ethanol  (I,  II,  III  and  IV-­‐‑PMA  cells),  0.1%  (IV-­‐‑THP-­‐‑1  cells)  or  0.01%  (V)).  
4.1.2  Samples  of  the  VitDmet  study  
73   individuals  participating   to   the  VitDmet  study  (NCT01479933,  ClinicalTrials.gov)   from  
the   region   of  Kuopio,   Finland   (63   °N)  were   supplemented   during   5  winter  months  with  
placebo,  40  or  80  µμg  vitamin  D3.  The  individuals  were  selected  to  be  ≥  60  years  of  age  with  
evidence   of   disturbed   glucose   homeostasis,   i.e.   impaired   fasting   glucose   or   impaired  
glucose  tolerance,  but  no  type  2  diabetes,  and  had  a  BMI  between  25  and  35.  The  research  
ethics  committee  of   the  Northern  Savo  Hospital  District  had  approved  the  study  protocol  
(#37/2011).   All   participants   gave   a   written   informed   consent   to   participate   in   the   study.  
Needle   biopsies   (0.5-­‐‑1   g)   from   subcutaneous   abdominal   adipose   tissue   were   taken   from  
47  individuals  (17,  14  and  16  individuals  supplemented  with  placebo,  40  or  80  µμg  vitamin  
D3,   respectively)   under   local   anesthesia   (10   mg/ml   lidocaine   without   adrenalin)   at   the  
beginning  and  the  end  of  the  study.  The  samples  were  washed  twice  with  PBS,  snap  frozen  
in  liquid  nitrogen  and  stored  at  -­‐‑80  °C  until  used  for  RNA  extraction.  
Serum   25(OH)D3   concentrations   were   measured   from   venous   blood   samples   using   a  
high  performance  liquid  chromatography  with  coulometric  electrode  array  (141).  The  blood  
samples   for  determining   the   25(OH)D3   concentrations  were   collected  at   the   same   time  as  
the   adipose   samples.   The   serum   25(OH)D3   concentrations   of   the   47  investigated   study  
participants  varied  at  the  beginning  of  the  study  between  35.9  and  73.6  nM  and  increased  in  
average   by   20.8   nM.   The  measurement   of   other   basic   clinical   and   biochemical   variables  
showed   that  neither   the  BMI  nor   the   serum  calcium  concentrations   significantly   changed  
during  the  intervention.  
4.2 METHODS 
4.2.1  RNA  extraction,  cDNA  synthesis  and  qPCR  
Cultured   cells   were   stimulated   for   indicated   time   periods   and   total   RNA  was   extracted  
using   the  High   Pure   RNA   Isolation  Kit   (Roche)   or   the  Quick   RNA  Miniprep  Kit   (Zymo  
Research)  following  manufacturer'ʹs  instructions.  Total  RNA  amount  was  quantified  with  a  
NanoDrop   ND-­‐‑1000   spectrophotometer.   cDNA   synthesis   was   performed   with   the  
Transcriptor  First  Strand  cDNA  Synthesis  Kit  (Roche)  using  1  µμg  (I,  II,  III,  IV)  or  500  ng  (V)  
of  total  RNA  as  a  template.  RNA  was  pre-­‐‑denaturated  for  10  min  with  oligo  (dT)18  primers  
at   65   °C   and   reverse   transcription   was   carried   out   for   30   min   at   55   °C   following   final  
denaturation   for  5  min  at  85   °C,  before   the  samples  were  diluted   to  400  µμl  with  nuclease  
free  water.  
Total  RNA   from  primary   adipose   samples   (V)  was   extracted  using   the  TRIzol  method  
followed  by  further  purification  using  the  miRNeasy  Mini  Kit  (Qiagen).  RNA  was  reverse  
transcribed   into   cDNA  using   the  High-­‐‑Capacity   cDNA  Archive  Kit   (Applied  Biosystems)  
following  manufacturer'ʹs  instructions.  
Real-­‐‑time   quantitative   polymerase   chain   reaction   (qPCR)   of   cDNA   templates   were  
performed  with   the  LightCycler   480   System   (Roche)   using   250   to   400   nM  of   reverse   and  
forward  primers  and  the  LightCycler  480  SYBRGreen  I  Master  mix  (Roche),  Maxima  SYBR  
Green/Fluorescein   qPCR   Master   Mix   (Fermentas)   or   Maxima   SYBR   Green/ROX   qPCR  
Master   mix   (Fermentas).   Hotstart   Taq   polymerase   was   activated   for   10   min   at   95   °C,  
followed  by  42  to  45  amplification  cycles  of  20  s  denaturation  at  95  °C,  15  to  20  s  annealing  
at  primer-­‐‑specific  temperatures  and  15  to  20  s  elongation  at  72  °C,  and  a  final  elongation  for  
10   min   at   72   °C.   PCR   product   specificity   was   monitored   using   post-­‐‑PCR   melt   curve  
analysis.  Relative  expression  levels  were  determined  for  each  sample  separately  relative  to  
the   reference   gene   ribosomal   protein,   large,   P0   (RPLP0)   (I,   III)   or   to   the   mean   of   the  




phosphate-­‐‑dehydrogenase   (GAPDH)   and   hypoxanthine   phosphoribosyltransferase   1  
(HPRT1)  (II,  IV),  or  RPLP0  and  GAPDH  (V)  using  the  formula  2-­‐‑(ΔCt),  where  ΔCt  is  Ct(target  gene)  
–  mean  of  Ct(reference   genes).  To  measure   the  effect  of  1,25(OH)2D3  stimulation,  relative  mRNA  
expression  levels  in  ligand-­‐‑treated  samples  were  compared  against  solvent  treated  control  
samples  to  obtain  fold  change  values.  
4.2.2  ChIP  
After   treatment   of   cells,   nuclear   proteins   were   cross-­‐‑linked   to   DNA   by   adding  
formaldehyde  directly  to  the  medium  to  a  final  concentration  of  1%  and  incubating  for  5  to  
10  min  at  room  temperature  on  a  rocking  platform.  Cross-­‐‑linking  was  stopped  by  adding  
glycine  to  a  final  concentration  of  0.125  M  and  incubating  at  room  temperature  for  5  min  on  
a  rocking  platform.  Adherent  cells  were  washed  with  ice-­‐‑cold  PBS  and  scraped  either  into  
PBS   (I)  or   into  Farnham  Lysis  buffer   (0.5%  NP-­‐‑40,  85  mM  KCl,  protease   inhibitors,  5  mM  
PIPES,   pH   8.0,   III,   IV   and  V)   and   then   pelleted   by   centrifugation.   Suspension   cells  were  
collected,  washed  with  ice-­‐‑cold  PBS  and  then  pelleted.  The  cell  pellets  were  resuspended  in  
lysis  buffer  (1%  SDS,  10  mM  EDTA,  protease  inhibitors  (Roche),  50  mM  Tris-­‐‑HCl,  pH  8.1)  
and   the   lysates  were   sonicated  using  a  Bioruptor  UCD-­‐‑200   (Diagenode,   I)   or   a  Bioruptor  
Plus   (Diagenode,   II   to  V).  Cellular  debris  was   removed  by   centrifugation   and   the   lysates  
were  diluted   1:10   in  ChIP  dilution  buffer   (0.01%  SDS,   1.1%  Triton  X-­‐‑100,   1.2  mM  EDTA,  
167  mM  NaCl,   protease   inhibitors,   250   µμg/ml   BSA,   16.7  mM  Tris-­‐‑HCl,   pH   8.1)   to   obtain  
output   samples   (immunoprecipitated  DNA).   For   input   samples,   the   lysates  were   diluted  
1:10  in  ChIP  dilution  buffer  without  protease  inhibitors  and  BSA.  
In   study   I,   one  µμg   of   antibodies   against  VDR   (sc-­‐‑1008),  HDAC4   (sc-­‐‑11418)   or  HDAC6  
(sc-­‐‑11420),   all   from   Santa   Cruz   Biotechnology,   or   acetylated   histone  H4   (06-­‐‑866)   or   non-­‐‑
specific   IgG   (12-­‐‑370),   both   from  Millipore,  were   added   to   output   samples   and   chromatin  
solutions   were   incubated   overnight   at   4   °C   with   rotation.   The   immuno-­‐‑complexes   were  
collected  with  60  µμl  of  protein  A  agarose  beads  (Millipore)  for  1  h  at  4  °C  with  rotation.  In  
the  studies  II  to  V,  one  µμg  of  antibodies  against  VDR  (sc-­‐‑1008,  Santa  Cruz  Biotechnology),  
CCCTC-­‐‑binding  factor  (CTCF,  07-­‐‑729,  Millipore,  III)  or  non-­‐‑specific  IgG  (12-­‐‑370,  Millipore)  
were  pre-­‐‑bound  to  20  µμl  of  Magna  ChIP  Protein  A  Magnetic  Beads  (Millipore)  or  60  µμl  of  
protein  A  agarose  beads  (Millipore,  IV-­‐‑THP-­‐‑1  cells)  in  3  h  to  overnight  incubations  at  4  °C  
with   rotation.   The   formed   bead-­‐‑antibody   complexes   were   washed   with   ChIP   dilution  
buffer   and   added   to   the   output   samples.   The   samples  were   incubated   overnight   at   4   °C  
with  rotation  to  form  the  immuno-­‐‑complexes.  
The   immuno-­‐‑complexes   were   then   washed   sequentially   for   4   min   with   the   following  
buffers:   low   salt   wash   buffer   (0.1%   SDS,   1%   Triton   X-­‐‑100,   2  mM   EDTA,   150  mM  NaCl,  
20  mM  Tris-­‐‑HCl,  pH  8.1),  high  salt  wash  buffer  (0.1%  SDS,  1%  Triton  X-­‐‑100,  2  mM  EDTA,  
500  mM  NaCl,   20  mM  Tris-­‐‑HCl,  pH  8.1)   and  LiCl  wash  buffer   (0.25  M  LiCl,   1%  Nonidet  
P-­‐‑40,   1%  sodium   deoxycholate,   1   mM   EDTA,   10   mM   Tris-­‐‑HCl,   pH   8.1).   Finally,   the  
immuno-­‐‑complexes   were   washed   twice   with   TE   buffer   (1   mM   EDTA,   10   mM   Tris-­‐‑HCl,  
pH  8.1,  I  or  pH  8.0,  II  to  V).  DNA  was  eluted  from  the  beads  with  buffer  (25  mM  Tris-­‐‑HCl,  
pH  7.5,  10  mM  EDTA,  0.5%  SDS)  in  a  30  min  incubation  at  65  °C  (I)  or  with  buffer  (1%  SDS,  
100  mM  NaHCO3)  in  two  15  to  20  min  elutions  at  room  temperature  with  rotation  (II  to  V).  
The  output  and  input  samples  were  reverse  cross-­‐‑linked  at  64  to  65  °C  for  5  h  to  overnight  
in   the   presence   of   proteinase   K   (Fermentas,   I   or   Roche,   II   to   V).   The  DNA  was   isolated  
either   with   the   ChIP   DNA   Clean   &   Concentrator   Kit   (Zymo   Research)   or   with  
phenol/chloroform/isoamyl   alcohol   (25:24:1)   extraction   followed   with   precipitation   using  
0.1   volume   of   3  M   sodium   acetate,   pH   5.2,   and   2   volumes   of   ethanol   with   glycogen   as  
carrier.   DNA   concentrations  were   determined   by  Quant-­‐‑iT   PicoGreen   dsDNA  Assay  Kit  
(Invitrogen).  
4.2.3  qPCR  of  chromatin  templates  
Genomic  primers  were  designed  for  the  VDR  or  CTCF  binding  regions  examined  in  these  




located  46  kb  upstream  of   the  CDKN1A   gene   (II,   III)   or   a   region   located  at   exon  2  of   the  
myoglobin  (MB)  gene  (IV,  V)  were  used.  In  study  I,  5’-­‐‑end  6-­‐‑carboxyfluorescein  and  3’-­‐‑end  
Black   Hole   Quencher   1   labeled   hydrolysis   probes   (Eurogentec)   were   used.   Selected  
genomic  regions  were  analyzed  with  qPCR  using  the  LightCycler  480  System  (Roche)  with  
400  nM  of  reverse  and  forward  primers,  25  nM  amplicon-­‐‑specific  probes  and  the  Maxima  
Probe  qPCR  master  mix  (Fermentas).  Hotstart  Taq  polymerase  was  thermally  activated  for  
10  min  at  95  °C,  followed  by  50  amplification  cycles  of  20  s  at  95  °C  and  60  s  at  60  °C.  The  
PCR  product  specificity  was  monitored  using  2%  agarose  gels.   In  studies  II   to  V,  selected  
genomic  regions  were  analyzed  with  qPCR  using  the  LightCycler  480  System  (Roche)  with  
250  to  400  nM  of  reverse  and  forward  primers  and  the  LightCycler  480  SYBRGreen  I  Master  
mix  (Roche).  Again  the  hotstart  Taq  polymerase  was  activated  with  a  10  min  at  95  °C  step,  
followed   by   43   to   45   amplification   cycles   of   20  s   denaturation   at   95  °C,   15  s   annealing   at  
primer-­‐‑specific  temperatures  and  15  s  elongation  at  72  °C,  and  a  final  elongation  for  10  min  
at  72  °C.  PCR  product  specificity  was  monitored  using  post-­‐‑PCR  melt  curve  analysis.  
Relative   association   of   chromatin-­‐‑bound   protein   or   histone   modifications   were  
normalized  with  respect  to  the  corresponding  input  using  the  formula  E-­‐‑(ΔCt)  x100%,  where  
E  is  amplification  efficiency  and  ΔCt  is  Ct(output)  –  Ct(input),  output  is  the  immuno-­‐‑precipitated  
DNA  and  input  is  the  purified  genomic  DNA.  
4.2.4  ChIP-­‐‑seq,  FAIRE-­‐‑seq  and  ChIA-­‐‑PET  data  visualization  
Genome-­‐‑wide  ChIP-­‐‑seq,  FAIRE-­‐‑seq  and  chromatin  interaction  analysis  with  paired-­‐‑end  tag  
sequencing   (ChIA-­‐‑PET)   data   was   visualized   for   the   studied   regions   (II   to   V)   to   get   an  
overview  of  the  VDR  and  CTCF  binding  sites,  active  or  accessible  chromatin  and  chromatin  
interactions,   respectively.   Publically   available  data   obtained   from  undifferentiated  THP-­‐‑1  
cells  were  used  for  VDR  ChIP-­‐‑seq  (GSE27437,  II,  III,  IV)  and  FAIRE-­‐‑seq  (GSE40075,  II,  III).  
VDR  ChIP-­‐‑seq  data  from  PMA-­‐‑differentiated  THP-­‐‑1  cells  (GSE51181)  was  obtained  during  
this   thesis   project   (II,   III,   IV).   In   study   V,   data   from   the   harmonized   analysis   of   six  
publically  available  VDR  ChIP-­‐‑seq  datasets  was  used  (GSE53041).  The  harmonized  analysis  
contained  VDR  ChIP-­‐‑seq  data  from  undifferentiated  THP-­‐‑1  cells,  LPS-­‐‑differentiated  THP-­‐‑1  
cells,  lymphoblastoid  cells  GM10855  and  GM10861,  hepatic  stellate  cells  LX2  and  colorectal  
cancer   cells   LS180.   All   of   the   above   mentioned   data   sets   are   available   at   GEO  
(www.ncbi.nlm.nih.gov/geo).  
Publically  available  datasets  of   the  ENCODE  consortium   (142)  were  downloaded   from  
UCSC  (http://genome.ucsc.edu/ENCODE).  ChIP-­‐‑seq  data  were  downloaded  for  CTCF  (III,  
IV)   and   histone   3   lysine   4   methylation   (H3K4me)   (IV)   from   K562   human   monocytic  
leukemia   cells   (CTCF,  wgEncodeEH002279;  H3K4me,  wgEncodeEH000400),   from   human  
umbilical   vein   endothelial   cells   (HUVEC;   CTCF,   wgEncodeEH000054;   H3K4me,  
wgEncodeEH000412)   and   from   normal   human   epidermal   keratinocytes   (NHEK;   CTCF,  
wgEncodeEH000063;  H3K4me,  wgEncodeEH000068).  ChIA-­‐‑PET  data  were  downloaded  for  
CTCF-­‐‑mediated  chromatin  loops  in  K562  cells  (wgEncodeEH002075,  II,  III,  IV).  
The   Integrative   Genomics   Viewer   (IGV)   (143)   was   used   to   visualize   ChIP-­‐‑seq   and  
FAIRE-­‐‑seq  data  and  the  UCSC  genome  browser  (144)  was  used  to  visualize  the  ChIA-­‐‑PET  
data.  
4.2.5  siRNA  inhibition  
In   study   I,   mRNA   expression   of   the   genes   HDAC4   and   HDAC6   was   inhibited   by  
transfecting  MCF-­‐‑10A  cells  with   siRNA  oligonucleotides  using  Lipofectamine  RNAiMAX  
reagent   (Invitrogen).   The   positive   surface   charge   of   the   reagent   mediates   interactions  
between  the  siRNAs  and  the  cell  membrane,  allowing  the  oligonucleotides  to  enter  the  cell.  
Three  specific  double-­‐‑stranded  siRNA  oligonucleotides  against   the   target  gene  were  used  
simultaneously   (200   pmol   of   each)   while   a   single   unspecific   double-­‐‑stranded  
oligonucleotide   served   as   a   control   (600   pmol).   The   siRNAs   were   diluted   in   500   µμl   cell  
culture  medium  without  antibiotics  and  serum.  5  µμl  RNAiMAX  reagent  was  added  and  the  




oligonucleotide  solution  were  combined  in  2.5  ml  cell  culture  medium  without  antibiotics  
and  with  horse   serum  (5%   final   concentration).  Transfected  cells  were  grown  24  h  before  
ligand  treatment.  
The   efficiency   of   siRNAs   to   inhibit   mRNA   expression  was  measured  with   qPCR   and  
silencing  at  the  protein  level  was  verified  by  western  blot  analysis  using  25  µμg  of  whole  cell  
extract.  Cellular  proteins  were  separated  on  12%  SDS  polyacrylamide  gels  and  the  blotted  
proteins  were  detected  using  specific  primary  antibodies  (see  chapter  4.2.2  ChIP)  or  anti-­‐‑β-­‐‑
actin  antibody  (Sigma-­‐‑Aldrich)  as  a   loading  control.  DyLight  800  conjugated  anti-­‐‑primary  
secondary  antibodies  (Thermo  Scientific)  were  used  to  detect  primary  antibodies.  Emissions  
from   the   conjugated   fluorophores   on   the   secondary   antibodies   were   detected   with   an  
Odyssey  reader  (Li-­‐‑Cor  Biotechnology).  
4.2.6  Correlation  analysis  
In   study   V,   the   participants   of   the   VitDmet   trial   were   ranked   according   to   their  
responsiveness   to   vitamin   D3.   The   ranking   was   done   under   the   assumption   of   a   linear  
positive  correlation  between  the  changes  of  the  mRNA  expression  of  the  four  studied  target  
genes,  DUSP10,   TRAK1,  NRIP1   and   THBD,   and   the   alterations   in   the   serum   25(OH)D3  
concentrations.  The  ranking  was  performed  for  each  target  gene  separately.  First,  the  study  
participants  were  sorted,  in  ascending  order,  according  to  their  ratios  between  the  changes  
of   the  gene  expression  and  serum  25(OH)D3  concentration.  Next,   starting   from  the  mean,  
individuals  were  ranked  both  in  ascending  and  descending  order  for  each  VDR  target  gene.  
Finally,  for  values  of  equal  rank  the  distance  of  the  value  to  the  mean  determined  the  final  
ranking.  
Linear   regression   analysis   between   changes   in   gene   expression   and   serum   25(OH)D3  
concentration  was  performed  using  Microsoft  Excel,  versions  2010  and  2011.  





5.1 DYNAMIC REGULATION OF 1,25(OH)2D3 TARGET GENES 
The   IGFBP3   gene   has   been   identified   as   a   primary   1,25(OH)2D3   target   gene   in   prostate  
cancer   cells   (36,93).   In   addition,   gene   regulation  by   a  number  of  NRs  has  been   shown   to  
follow  a  dynamic  pattern  (76,77).  To  find  out  whether  IGFBP3  is  a  1,25(OH)2D3  target  gene  
also   in  mammary   cells   and   to   evaluate   the  dynamics   of   its   transcription,   15  min   interval  
1,25(OH)2D3   treatments  were  performed  using  MCF-­‐‑10A,  an   immortalized  normal  human  
mammary   epithelial   cell   line.   The   IGFBP3   gene   was   up-­‐‑regulated   dynamically   by  
1,25(OH)2D3,   while   its   up-­‐‑regulation   by   the   synthetic   vitamin   D   analog   Gemini   was   not  
fluctuating   (I,   Figure   1).   In   addition,   the   induction   of   the   IGFBP3   gene   in   response   to  
Gemini   treatment   was   more   potent,   showing   a   5.5-­‐‑fold   up-­‐‑regulation   after   240   min  
treatment,  while  1,25(OH)2D3  stimulation  caused  only  a  2.6-­‐‑fold  induction.  
Previous  studies  have  characterized  two  VDR  binding  sites  within  the  IGFBP3  promoter,  
which   are   called   RE1/2   and   RE3   (36,93).   ChIP   analysis   of   VDR   binding   showed   parallel  
cyclical   VDR   association   on   the   both   VDR   binding   sites   in   response   to   1,25(OH)2D3   (I,  
Figure   2).   In   contrast,   after   Gemini   treatment,   VDR   binding   to   these   regions   was   more  
linear.  In  addition,  Gemini  induced  more  VDR  binding  on  RE3  at  all  measured  time  points,  
while  on  RE1/2  the   ligand-­‐‑induced  maximal  VDR  binding  was  stronger  after  1,25(OH)2D3  
treatment.  
Interestingly,   from   all   11   human  HDAC   genes   only  HDAC4   and  HDAC6   respond   to  
1,25(OH)2D3   treatment   in   a   dynamic   fashion,   while   no   up-­‐‑regulation   of   the   genes   was  
observed   in   response   to   Gemini   (I,   Figure   3).   The   association   of   HDAC4,   HDAC6   and  
chromatin  activation  measured  by  histone  4  acetylation  was  analyzed  by  ChIP,  in  order  to  
study  the  dynamics  of  a  physical  HDAC  association  with  the  two  VDR  binding  sites  of  the  
IGFBP3  promoter.  Strong  HDAC4  binding  was  found  to  coincide  with  low  VDR  binding  at  
the  same  time  point.  Both   ligands   induced  the  reduction  in  HDAC4  and  HDAC6  binding  
after  15  to  45  min  treatment.  To  evaluate  the  hypothesis  that  transcriptional  cycling  of  the  
IGFBP3  gene  originates  from  the  actions  of  HDAC4  and  HDAC6,  a  simultaneous  silencing  
of  HDAC4   and  HDAC6  mRNA  expression  was  performed.  After   the  knock-­‐‑down  of  both  
genes,   the   cyclical   up-­‐‑regulation   of   the   IGFBP3   gene   by   1,25(OH)2D3   diminished   (I,  
Figure  5)   suggesting   that   the  dynamic  response  of   the   IGFBP3  gene   is  based  on  a  cyclical  
association  of  VDR,  HDAC4  and  HDAC6  on  the  gene  promoter.  
Transcriptional  cycling  of  the  gene  IGFBP3  was  not  observed  in  human  RWPE-­‐‑1  prostate  
epithelial   cells   (I,   Figure   S2).   Furthermore,   in   studies   II   to   IV,  which  were   performed   in  
THP-­‐‑1   monocytic   cell   line   models,   no   similar   cycling   of   mRNA   levels   of   primary  
1,25(OH)2D3  target  genes  that  were  investigated  in  these  studies  was  detected  (II,  Figure  1;  
III,   Figures   2B-­‐‑D   and   4B-­‐‑D;   IV,   Figures   1D   and   E).   Some   of   the   genes   showed   a   non-­‐‑
continuous   up-­‐‑regulation,   such   as   CDKN1A   (II,   Figure   1B),   CXCL6   (III,   Figure   2C)   and  
CXCL1  (III,  Figure  2D),  but  all  mRNA  time  course  experiments  had  been  performed  using  
30  min  intervals  and  showed  relatively  high  variation.  Therefore,  monitoring  cyclical  events  
remains  challenging.  In  study  V,  primary  1,25(OH)2D3  target  genes  were  studied  in  human  
SGBS   pre-­‐‑adipocytes   with   60   min   intervals,   therefore   possible   cycling   could   not   be  
detected.  In  addition,  no  time  course  ChIP  experiments  were  performed  in  studies  II  to  V.  
Therefore,   the  dynamic  association  of  VDR  on  the  regulatory  region  of   these   target  genes  




5.2 VDR BINDING PROFILE IN THE REGIONS OF STUDIED 1,25(OH)2D3 
TARGET GENES 
Primary   target   gene   activation   by   1,25(OH)2D3   is  mediated   exclusively   via   VDR   binding  
upstream   or   downstream   of   the   target   gene’s   TSS.   The   genome-­‐‑wide   analysis   of   VDR  
binding  sites  has  revealed  a   large  variation   in   the  distance  of  VDR  binding  sites   from  the  
target   gene’s   TSS,   in   the   number   of  VDR  binding   sites  within   the   genomic   region   of   the  
target  gene  and   in   the  number  of   target  genes   that  are   regulated  by   the   same  VDR   locus  
(81).   In   addition,   a   harmonized   analysis   of   six   different   VDR   ChIP-­‐‑seq   datasets   (71)  
demonstrated  that  most  VDR  binding  sites  are  cell  type-­‐‑specific.  Therefore,  it  is  essential  to  
create   a  general  view  on   the  VDR  binding  profile   in   the  used   cellular  model,   in  order   to  
understand  the  effects  of  1,25(OH)2D3  on  the  studied  genomic  region.  
The   size   of   the   chromosomal   regulatory   domains   can   be   estimated   by   DNA   looping  
mediated  by  the  transcription  factor  CTCF  (145).  The  high  conservation  of  genomic  CTCF  
binding  sites  (146)  allows  a  reliable  extrapolation  of  CTCF  ChIP-­‐‑seq  data  from  K562  cells,  
which   are   also   human  monocytic   leukemia   cells   (147),   to   THP-­‐‑1   cells.   Publicly   available  
genome-­‐‑wide  CTCF  ChIP-­‐‑seq  and  CTCF  ChIA-­‐‑PET  data  (142),  which  were  obtained  from  
K562  cells,  were  used  to  evaluate  the  size  of  the  chromosomal  region  around  VDR  binding  
sites.  In  addition,  conservation  of  the  CTCF  binding  was  confirmed  by  using  the  ChIP-­‐‑seq  
data  derived  from  HUVEC  and  NHEK  cells,  which  are  far  more  distinct  from  THP-­‐‑1  cells  
than  K562  cells.  The  information  about  DNA  looping,  derived  from  ChIA-­‐‑PET  data  (II,  III,  
IV),  as  well  as  CTCF  binding  data  derived  from  ChIP-­‐‑seq  data  (III,  IV),  were  used  to  assess  
the  size  of  the  VDR-­‐‑regulated  chromosomal  domain.  Additionally,  the  binding  of  CTCF  to  
sites,  which  were  described  in  public  datasets,  was  confirmed  in  monocytes  by  ChIP-­‐‑qPCR  
(III,   Figure   1B).   In   order   to   have   a   general   view  on   the  VDR  binding  profile   in   the   used  
THP-­‐‑1  cell  models  (II,  III,  IV),  i.e.  monocytes  (non-­‐‑differentiated)  and  macrophages  (PMA-­‐‑
differentiated),   VDR   ChIP-­‐‑seq   data   were   obtained   (macrophages)   or   taken   form   a  
previously  published  study  (monocyte  (81))  and  used  in  the  visualizations.  
The   visualization   of   VDR   binding   data   revealed   that   the   genomic   regions   around   the  
three   investigated   cancer-­‐‑associated   1,25(OH)2D3   target   genes,  G0S2,   CDKN1A   and  MYC,  
contained  one  to  four  VDR  binding  sites.  Only  some  of  these  sites  carried  a  DR3-­‐‑type  motif  
(II,  Figure  2).  The  genomic  region  surrounding  the  G0S2  gene  contains  only  one  VDR  peak  
with  a  DR3-­‐‑type  motif,  which  was  active  both   in  monocytes  and  macrophages   (II,  Figure  
2A).  In  contrast,  in  the  region  of  the  CDKN1A  gene  three  active  VDR  binding  sites,  of  which  
two  carry  a  DR3-­‐‑type  sequence,  were  active  in  monocytes,  but  none  of  them  were  occupied  
in  macrophages  (II,  Figure  2B).  Moreover,  in  the  region  of  the  MYC  gene  from  the  four  VDR  
binding  sites  that  were  observed  in  monocytes,  only  the  two  that  contain  a  DR3-­‐‑type  motif  
were  used  in  macrophages  (II,  Figure  2C).  In  study  III,  the  isolated  genomic  region  around  
the  CXCL  chemokine  cluster  was  found  to  contain  only  one  VDR  binding  locus  (carrying  a  
DR3-­‐‑type  motif)   in  monocytes   that  was  occupied  also   in  macrophages   (III,  Figure  5A).   In  
contrast,   the   prominent   primary   1,25(OH)2D3   target   gene   ASAP2  was   activated   both   in  
monocytes   and   macrophages   by   three   VDR   binding   sites   (IV,   Figure   2A),   all   of   which  
contain  a  DR3-­‐‑type  binding  motif.  
Taken   together,   all   studied   chromosomal   domains   have   individual   VDR   binding  
characteristics  concerning  the  number  of  active  VDR  binding  loci  with  and  without  a  DR3-­‐‑
type  binding  motifs.  
5.3 1,25(OH)2D3 TARGET GENES IN MONOCYTES AND MACROPHAGES 
5.3.1  Cancer-­‐‑associated  1,25(OH)2D3  target  genes  
In   study   I   the   regulatory  mechanism   of   the   VDR-­‐‑mediated   up-­‐‑regulation   of   the   IGBFP3  




anti-­‐‑cancer   functions   in   breast   cancer   and   a   significant   role   in   1,25(OH)2D3-­‐‑induced  
apoptosis   (34).   To   increase   the   knowledge   of   1,25(OH)2D3-­‐‑mediated   growth   inhibition   in  
THP-­‐‑1  myelomonocytic   leukemia  cell  models,   three  known  cancer-­‐‑associated  1,25(OH)2D3  
target  genes,  G0S2,  CDKN1A  and  MYC,  were  selected  for  study  II.  In  both  undifferentiated  
THP-­‐‑1  cells  (monocytes)  and  PMA-­‐‑differentiated  THP-­‐‑1  cells  (macrophages)  the  G0S2  gene  
was  shown  to  be  an  up-­‐‑regulated  primary  1,25(OH)2D3  target,  being  significantly  induced  
after  1  h  of   ligand   treatment   (II,  Figure  1A).  Although   the  basal  mRNA  expression  of   the  
G0S2   gene   was   higher   in   macrophages,   the   gene   showed   far   stronger   inducibility   in  
macrophages  than  in  monocytes  (5.3-­‐‑fold  and  2.6-­‐‑fold  inductions,  respectively,  after  8  h  of  
ligand  treatment)  (II,  Figures  1A  and  S1).  The  gene  CDKN1A  showed  a  faint  but  significant  
response  to  1,25(OH)2D3  treatment  in  both  cellular  models  (II,  Figure  1B).  The  up-­‐‑regulation  
was   significant   2.5   h   after   ligand   treatment   in   both   cell   types   but   the  maximal   induction  
was   only   1.6-­‐‑fold   in   monocytes   and   even   as   low   as   1.3-­‐‑fold   in   macrophages.   The   basal  
mRNA   expression   level   of   the  CDKN1A   gene  was   about   the   same   in   both   cell   types.   In  
contrast  to  the  up-­‐‑regulation  of  the  genes  G0S2  and  CDKN1A,  the  MYC  gene  showed  slight  
tendency   towards   down-­‐‑regulation   in  monocytes   (II,   Figure   1C).   Interestingly,  when   the  
cells  were  differentiated   to  macrophages,  MYC   turned  out   to  be  an  early   responding  up-­‐‑
regulated  1,25(OH)2D3  target  gene.  Differentiation  reduced  basal  mRNA  expression  level  of  
the  gene  as  well.  
In  order  to  estimate  the  number  of  VDR  binding  sites  around  the  genes  G0S2,  CDKN1A  
and  MYC,  the  sizes  of  the  chromosomal  regulatory  domains  containing  the  respective  genes  
were  assessed  by  DNA  looping  mediated  by   the   insulator  protein  CTCF  (based  on  CTCF  
ChIA-­‐‑PET  data   (142);   II,  Figure  S3).  Visualization  of  VDR  ChIP-­‐‑seq  data   from  monocytes  
(81)  and  macrophages  showed  that  the  genomic  region  containing  the  G0S2  gene,  which  is  
at  maximum  180  kb  of  size,  contains  only  one  VDR  binding  site  located  15  kb  upstream  of  
the  gene’s  TSS  (II,  Figures  2A  and  S3A).  The  VDR  binding  site  is  active  both  in  monocytes  
and   macrophages   and   is   contained   within   all   possible   CTCF-­‐‑mediated   DNA   loops   (II,  
Figures  2A  and  S3A).  In  addition,  the  site  has  a  significant  level  of  accessible  chromatin,  as  
determined   by   FAIRE-­‐‑seq   (86),   which   is   further   induced   in   response   to   1,25(OH)2D3  
treatment  (II,  Figure  3).  ChIP-­‐‑qPCR  data  from  monocytes  revealed  that  among  all  studied  
VDR  binding  sites,  the  site  near  the  G0S2  gene  represents  that  with  the  highest  inducibility.  
The   chromatin   loops   around   the  CDKN1A   gene   cover   170   kb   and   contain   three   VDR  
binding   sites   that   all   are   in   a   region  of   open   chromatin   in  monocytes   (II,   Figures   2B   and  
S3B).   However,   not   all   the   DNA   loops   contain   VDR   binding   loci   2   and   3.   ChIP-­‐‑qPCR  
experiment  could  not  confirm  the  binding  of  VDR  to  site  1,  although  it  was  suggested  by  
VDR  ChIP-­‐‑seq   data.   This   site   has   a   relatively   high   rate   of   open   chromatin   (II,   Figure   3).  
VDR   sites   2   and   3   were   ligand-­‐‑inducible,   but   site   3   shows   higher   basal   VDR   binding.  
Interestingly,   no   VDR   binding   to   these   or   any   additional   sites   was   observed   in  
macrophages.  
The  large  chromosomal  domain  around  the  MYC  gene  covers  2.8  Mb  and  contains  four  
VDR  binding  sites  in  monocytes  (II,  Figures  2C  and  S3C).  Open  chromatin  was  observed  at  
VDR  loci  2,  3  and  4,  of  which  the  latter  showed  the  highest  rates  of  open  chromatin  among  
all  studied  VDR  binding  sites  (II,  Figure  3).  Interestingly,  only  the  two  loci  containing  DR3-­‐‑
type  motifs  were  occupied  also  in  macrophages.  In  monocyte  ChIP-­‐‑seq  data,  VDR  binding  
was  down-­‐‑regulated   in  response  to  1,25(OH)2D3   treatment  at  site  1,  which   is   the  only  site  
without  open   chromatin   among  all   studied   sites.  This  down-­‐‑regulation  was  however  not  
observed   after   one   hour   treatment   in   the   ChIP-­‐‑qPCR   experiment,   although   strong   basal  
VDR  binding  was  found  (II,  Figure  3).  
In   summary,   the   observed   diversity   of   mRNA   inductions   in   the   studied   genes,   is  
originating  from  the  unique  VDR  binding  profile  to  the  respective  regulatory  regions  of  the  
three  studied  genes.  In  addition,  in  the  genomic  regions  of  the  genes  CDKN1A  and  MYC  the  




5.3.2  The  CXCL  gene  cluster  
The  CXCL   gene   cluster   on   chromosome   4   contains   nine   genes   encoding   the   chemokines  
CXCL1   to   CXCL8   and   CXCL4.1.   Analysis   of   previously   published   VDR   ChIP-­‐‑seq   and  
microarray   data   (81)   suggested   the   CXCL8   gene   as   a   1,25(OH)2D3   target   in   THP-­‐‑1  
monocytes.  The  gene  CXCL8,  also  known  as  IL8,  is  a  major  neutrophil  chemoattractant  and  
was  the  first   identified  chemokine  (124,130).  The  responsiveness  of  CXCL8   to  1,25(OH)2D3  
gave   initiation   to   study   III,   in  which   the   impact   of   1,25(OH)2D3   on   the   regulation   of   the  
whole  CXCL  chemokine  cluster  was   investigated.  Visualization  of  publicly  available  data  
for  CTCF  ChIP-­‐‑seq  and  CTCF  ChIA-­‐‑PET  (142)  and  a  ChIP-­‐‑qPCR  analysis  for  CTCF  binding  
suggested  that  the  whole  CXCL  gene  cluster,  but  not  any  other  gene,  belongs  to  the  same  
chromosomal  domain  that  is  isolated  by  bordering  CTCF  sites  (III,  Figure  1).  Interestingly,  
visualization   of   FAIRE-­‐‑seq   data   from   monocytes   (86)   indicated   high   rates   of   accessible  
chromatin   in   the   region   spanning   the   genes   CXCL8,   CXCL6,   CXCL4.1   and   CXCL1   (III,  
Figure  1A).  
VDR   ChIP-­‐‑seq   analysis   in   THP-­‐‑1   monocytes   highlighted   a   prominent   1,25(OH)2D3-­‐‑
inducible   VDR   binding   site   between   the   genes   CXCL6   and   CXCL8,   located   22  kb  
downstream  of   the  CXCL8  TSS   (III,  Figures  1A  and  3A).   In  addition,  VDR  ChIP-­‐‑seq  data  
from   PMA-­‐‑differentiated   THP-­‐‑1   macrophages   (III,   Figure   5A)   showed   that   this   site   is  
ligand-­‐‑inducible   also   in   macrophages.   VDR   binding   and   inducibility   in   response   to  
1,25(OH)2D3   was   confirmed   by   ChIP-­‐‑qPCR   experiments   performed   in   monocytes   and  
macrophages  (III,  Figures  3B  and  5B,  respectively).  Furthermore,  FAIRE-­‐‑seq  data  indicated  
that  the  VDR  locus  is  accompanied  with  accessible  chromatin  (III,  Figure  3A).  In  addition,  
FAIRE-­‐‑seq   time   course   data   revealed   ligand-­‐‑inducible   chromatin   opening   at   this   site   in  
monocytes.  
To  gain  an  overview  on  the  whole  CXCL  gene  cluster,  relative  basal  mRNA  expression  
levels  of  the  genes  of  the  cluster  and  its  flanks  were  measured  by  qPCR.  In  monocytes,  only  
the  genes  CXCL1,  CXCL6  and  CXCL8  were  expressed  (III,  Figure  2A).  All   three  genes  are  
up-­‐‑regulated  primary  1,25(OH)2D3  target  genes  that  display  significant  induction  already  1  
h   after   stimulation   (III,   Figures   2B-­‐‑D).   CXCL8   demonstrated   highest   basal   expression  
accompanied  with  most  pronounced  inducibility,  9.1-­‐‑fold  after  8  h  1,25(OH)2D3  stimulation,  
of  the  three  genes.  No  induction  of  the  flanking  genes  was  observed.  The  basal  expression  
of   the  CXCL   cluster   in  macrophages   indicated   two  additional   genes,  CXCL3   and  CXCL7,  
but   neither   of   them   responded   to   1,25(OH)2D3   treatment   (III,   Figures   4A   and   S2).   In  
macrophages,   the   gene  CXCL8   showed   a   33-­‐‑fold   increased   basal   expression,   while   only  
slightly   higher   basal   expression   levels   of   CXCL1   and   CXCL6   were   observed   when  
compared  to  monocytes  (III,  Figure  4).  Although  all  three  genes  were  primary  1,25(OH)2D3  
targets   also   in  macrophages,   they   exhibited  delayed   response   to   1,25(OH)2D3   stimulation  
and   showed   attenuated  maximum   induction   compared   to  monocytes   (III,   Figures   4B-­‐‑D).  
For   example,   the   first   significant   induction   of   the  CXCL8   gene   was   detected   3.5   h   after  
1,25(OH)2D3  stimulation  and  even  8  h  after  the  induction  with  hormone  was  only  1.9-­‐‑fold.  
Taken   together,   1,25(OH)2D3   regulates   specifically   the   expression   of   the   inflammatory  
cytokine  genes  CXCL1,  CXCL6  and  CXCL8  in  both  monocytes  and  macrophages.  However,  
the  induction  is  reduced  in  macrophages,  where  the  basal  expression  of  the  genes  is  higher.  
5.3.3  The  ASAP2  gene  
Analysis   of   the   previously   published   VDR   ChIP-­‐‑seq   and   microarray   study   in   THP-­‐‑1  
monocytes   (81)  highlighted   the  genomic   region   around   the  ASAP2   gene   containing   three  
strongly   inducible   VDR   binding   sites,   each   of   which   is   carrying   a   DR3-­‐‑type   motif   (IV,  
Figure  1A).  The  region  around  the  ASAP2  gene  contains  also  the  genes  ITGB1BP1,  CPSF3,  
IAH1,  ADAM17,  YWHAQ  and  TAF1B.  Publicly  available  ChIP-­‐‑seq  data   for  CTCF  binding  
(142)  were  visualized,  in  order  to  evaluate  the  size  of  the  chromosomal  domain  around  the  
three  VDR  binding  sites.  Using  ChIP-­‐‑seq  data  for  H3K4me  (142),  CTCF  binding  sites,  which  




excluded.   CTCF   binding   and   ChIA-­‐‑PET   data   confirmed   that   the   chromosomal   domain  
around   the  ASAP2   gene   contains  up   to   three  VDR  binding   sites   (IV,  Figures   1A  and  S1).  
Interestingly,  VDR  binding  data  revealed  that  in  response  to  1,25(OH)2D3  all  three  binding  
sites  show  a  similar  pattern  of  VDR  association  in  monocytes  and  PMA-­‐‑differentiated  THP-­‐‑
1  macrophages   (IV,  Figure  2A).  Site  2  displayed  hormone   independent  VDR  binding,  but  
was  also  ligand  inducible.  In  contrast,  sites  1  and  3  were  occupied  by  the  receptor  only  after  
1,25(OH)2D3  stimulation.  From  the  three  VDR  loci,  site  1  exhibited  the  strongest  inducibility  
in  response  to  1,25(OH)2D3.  VDR  ChIP-­‐‑seq  data  were  confirmed  by  ChIP-­‐‑qPCR  performed  
in  both  monocytes  and  macrophages  (IV,  Figure  2B).  
With  the  aim  to  get  a  general  view  on  the  relative  basal  mRNA  expression  profile  of  the  
genes   in   the  whole   chromosomal  domain   comprising   the   three  VDR  binding   sites,   qPCR  
was   performed   in   both   monocytes   and   macrophages   (IV,   Figure   1B).   All   genes   in   the  
studied   region  were   expressed   in   both   cellular  models.  However,   only   the  ASAP2   gene,  
which   displayed   rather   low   expression   levels   in   monocytes,   showed   a   difference   in   the  
basal   expression   levels   in   comparison   of   both   cellular   models,   being   77-­‐‑fold   higher  
expressed  in  macrophages.  In  addition,  the  ASAP2  gene  responded  more  prominently  and  
faster   to   1,25(OH)2D3   treatment   in   monocytes   than   in   macrophages,   reaching   a   3.8-­‐‑fold  
induction  already  2.5  h  after   ligand   stimulation   (IV,  Figures  1D  and  E).  Furthermore,   the  
ASAP2  gene  was  demonstrated  to  be  the  only  primary  target  of  1,25(OH)2D3  in  the  studied  
genomic  region  (IV,  Figure  S2).  
In  summary,   the   ligand-­‐‑induced  binding  of  VDR  to   the   three  sites   in   the  studied   locus  
leads  to  the  up-­‐‑regulation  of  only  one  gene,  ASAP2.  
5.4 1,25(OH)2D3 TARGET GENES IN HUMAN ADIPOCYTES 
In  study  V,  primary  1,25(OH)2D3  target  genes  and  VDR  binding  sites  were  characterized  in  
the   human   SGBS   pre-­‐‑adipocyte   cell   line,   for  which   no  VDR  ChIP-­‐‑seq   data   are   available.  
However,   a   recent   analysis   combining   all   public   VDR   ChIP-­‐‑seq   datasets   indicated   55  
conserved  VDR  binding  regions  (71)  (V,  Table  S4).  Due  to  the  ubiquity  in  VDR  binding  in  
the  available  cell  lines  to  these  sites,  these  genomic  loci  are  most  likely  occupied  by  VDR  in  
SGBS  cells.  From  the  55  VDR  loci,  four  sites  located  upstream  of  the  genes  DUSP10,  TRAK1,  
NRIP1  and  THBD  were  selected  for  further  investigations  (V,  Figure  1).  Association  of  VDR  
with   these   sites   in   pre-­‐‑adipocytes   was   confirmed   by   ChIP-­‐‑qPCR   (V,   Figure   2).   After  
treatment  for  1  and  2  h  with  1,25(OH)2D3  the  VDR  binding  was  increased  at  the  sites  of  the  
genes  DUSP10,  NRIP1  and  THBD,  whilst  the  site  of  the  TRAK1  gene  showed  VDR  binding  
already   in   the   absence   of   ligand   that   was   not   further   induced   by   ligand   treatment.  
Furthermore,  the  mRNA  expression  levels  of  the  genes  DUSP10,  TRAK1,  NRIP1  and  THBD  
were   induced   in   response   to   1,25(OH)2D3   in   SGBS   cells   confirming   that   these   genes   are  
primary  1,25(OH)2D3   target  genes   and   regulated  by   conserved  VDR  binding   sites   located  
upstream  of  the  genes  (V,  Figure  3).  
In   order   to   increase   our   understanding   about   the   physiological   consequence   of   the  
1,25(OH)2D3   responsiveness   of   the   genes  DUSP10,   TRAK1,  NRIP1   and   THBD   in   human  
adipocytes,   the   expression   levels   of   the   genes   were   studied   in   human   adipose   tissues  
samples,   which   were   obtained   by   peripheral   subcutaneous   needle   biopsies   from  
47  participants  of  the  VitDmet  study.  During  this  5-­‐‑month  intervention  trial,  adipose  tissue  
samples  were  collected  and  serum  25(OH)D3  concentrations  were  measured  at  the  start  and  
end  of   the   intervention.  The  changes   in   serum  25(OH)D3   levels  varied  between  a  2.1-­‐‑fold  
decrease  and  a  2.4-­‐‑fold  increase,  while  changes  in  the  mRNA  expression  of  the  four  genes  
in   the   adipose   tissue   samples   ranged   from   a   4.71-­‐‑fold   decrease   of   THBD   to   a   3.15-­‐‑fold  
increase  of  NRIP1  (V,  Table  S1).  
The   study   participants   were   ranked   for   each   of   the   four   primary   VDR   target   genes  




the   respective   changes   in   serum   25(OH)D3   concentrations   during   the   intervention   (V,  
Table  S2).  In  order  to  evaluate  the  assumed  correlations,  the  correlation  coefficient  (r)  was  
calculated  between  expression   level   changes  and  serum  25(OH)D3  concentration  changes.  
Study  participants  were   then  removed  one  after   the  other   in  reverse  order  based  on  their  
ranking;   the   r-­‐‑values   were   re-­‐‑calculated   again   after   each   step.   The   r-­‐‑values   and   the  
respective  number  of  remaining  study  participant  were  plotted,  to  identify  the  number  of  
remaining  participants  showing  an  r-­‐‑value  of  at  least  0.71  (r2  >  0.5)  (V,  Figure  4).  From  the  
four   studied   genes,   DUSP10   identified   30   participants   showing   the   highest   number   of  
individuals  among  the  studied  genes.   Interestingly,  when  only  the  participants  with  an  r-­‐‑
value   of   at   least   0.71   were   visualized   in   correlation   graphs,   with   the   exception   of   one  
subject,   the   gene  DUSP10   described   the   same   group   of   persons   (but   7   and   8   additional  
individuals)  as  those  identified  by  genes  TRAK1  and  NRIP1  (V,  Figure  5).  
In   summary,   the   genes  DUSP10,   TRAK1,  NRIP1   and   THBD   are   primary   1,25(OH)2D3  
targets  in  pre-­‐‑adipocytes  and  are  regulated  by  conserved  VDR  binding  sites.  The  genes  can  
be  used  as  markers  for  the  vitamin  D3  response  of  human  individuals,  of  which  DUSP10  is  
the  most  suitable.  





The   secosteroid   vitamin   D3   is   a   pro-­‐‑hormone   involved   in   a   variety   of   cellular   and  
physiological  functions.  The  active  form  of  vitamin  D3,  1,25(OH)2D3,  mediates  its  biological  
responses  through  the  NR  VDR.  VDR  binds  directly  to  genomic  DNA  and  regulates  target  
gene   expression   when   activated   by   ligand.   VDR   is   widely   expressed   and   is   the   only  
mediator  for  the  genomic  actions  of  1,25(OH)2D3.  Therefore,  characterizing  i)  tissue-­‐‑specific  
genomic  VDR  locations,  ii)  molecular  actions  of  VDR  regulation  on  gene  expression  and  iii)  
tissue-­‐‑specific   VDR   target   genes   is   of   high   impact,   in   gaining   more   insight   into   the  
physiological  function  of  vitamin  D3.  
In  the  present  thesis,  the  mechanism  of  the  gene  regulation  by  VDR  was  studied  at  the  
example  of   the  gene   IGFBP3,   in  order   to  describe   the  differences   in   the  mRNA  induction  
while  using  natural  VDR   ligand  1,25(OH)2D3  or   its   synthetic   analogue  Gemini.   In   further  
studies,   primary   VDR   target   genes   involved   in   growth   inhibition,   inflammation   and  
intracellular   signaling   were   characterized   in   THP-­‐‑1  monocytes   and  macrophages.   In   the  
final  study,  conserved  VDR  target  genes  were  characterized  in  human  pre-­‐‑adipocytes  and  
the   genes   were   further   studied   in   primary   human   adipose   tissue   samples,   in   order   to  
identify  biomarkers  representing  the  vitamin  D  status  of  human  individuals.  
6.1 THE IGFBP3 GENE IS REGULATED DYNAMICALLY BY 1,25(OH)2D3 
In  the  first  part  of  this  thesis  (study  I),  the  regulation  of  the  well-­‐‑known  1,25(OH)2D3  target  
gene   IGFBP3  was   investigated  using   the   cell   line  MCF-­‐‑10A.   In   this   study,   the  previously  
reported   up-­‐‑regulation   (36,93)   of   the   IGFBP3   gene   in   response   to   1,25(OH)2D3   was  
confirmed.  The  ability  of  1,25(OH)2D3  to  induce  IGFBP3  mRNA  2.5-­‐‑fold  after  4  h  treatment  
was   comparable   to   previously   reported   results   in   prostate   cancer   cell   lines   (36,93).   In  
response   to   1,25(OH)2D3,   cyclical   mRNA   accumulation   of   the   IGFBP3   gene   was  
demonstrated  with  phases  of  RNA  synthesis  and  degradation,  with  a  periodicity  of  60  min.  
In  contrast,   the  synthetic  1,25(OH)2D3  analog  Gemini  showed  linear  and  stronger  (5.5-­‐‑fold  
induction  after  4  h)  up-­‐‑regulation  of  the  gene.  In  the  previous  studies  (36,93)  the  regulation  
of   IGFBP3   by   1,25(OH)2D3   was   studied   based   on   a   limited   number   of   time   points   and  
therefore   transcriptional   cycling   of   IGFBP3   in   these   cell   lines   had   not   been   described.   In  
addition,   the   observed   dynamics   in   IGFBP3   mRNA   accumulation   seems   to   be   cell   type  
specific,   since  no   transcriptional  cycling  was  observed,  when  the  gene  was  studied  under  
identical  conditions  in  RWPE-­‐‑1  immortalized  prostate  cells.  
A  cyclical  induction  of  a  VDR  target  gene,  CDKN1A,  has  been  observed  earlier  in  MDA-­‐‑
MB453  breast  cancer  cells  (76).  In  addition,  NR-­‐‑induced  target  gene  expression  was  found  
to   include   cyclical   association   of   the   receptor,   RNA   polymerase   II   and   co-­‐‑factors   on  
respective   gene  promoters   (77,78).   To  have   a   broader  view  on   the   cyclical   induction  of   a  
VDR   mediated   transcription,   association   of   VDR,   HDAC4   and   HDAC6   and   chromatin  
activation  were  examined  in  study  I  on  two  previously  characterized  VDR  binding  regions  
on  the  IGFBP3  promoter.  On  region  1/2,  which  is  located  closer  to  the  gene’s  TSS,  VDR  was  
slightly  more   prominently   associated   after   1,25(OH)2D3   treatment  when   compared   to   the  
VDR  association  induced  by  Gemini.  In  addition,  the  natural  VDR  ligand  induced  parallel  
cyclical  VDR  association  on  both  regions,  while  the  VDR  association  in  response  to  Gemini  
was  more  linear  on  both  regions.  Although  in  general,  lower  levels  of  VDR  association  were  
observed   on  RE3,   the   binding   of  VDR  was  more   prominent   after  Gemini   treatment   than  




induced  steady  up-­‐‑regulation  of  the  IGFBP3  gene  is  primarily  based  on  the  ligand-­‐‑induced  
binding  of  VDR  to  region  3.  
Interestingly,   high   ligand-­‐‑induced   VDR   association   corresponded   to   low   HDAC4  
association,  which  suggests   that  during   transcriptional  cycling  VDR  and  HDAC4  binding  
occur   in   different   phases.   In   addition,   the   reduction   in   both   HDAC4   and   HDAC6  
association  after  15  to  45  min  ligand  treatment  coincides  with  an  induction  of  VDR  binding  
at  the  same  time  points.  Furthermore,  in  response  to  1,25(OH)2D3  the  chromatin  activation  
at  region  1/2  displayed  cycling  with  similar  interval  as  accumulation  of  IGFBP3  mRNA.  In  
addition,   changes   in  HDAC6   association  was   observed   only   at   region   1/2   in   response   to  
1,25(OH)2D3  treatment,  while  after  Gemini  treatment  the  association  of  HDAC6  was  rather  
similar  with  both  regions.  These  observations  suggest  that  the  transcriptional  cycling  of  the  
IGFBP3   gene   is   primarily   mediated   by   VDR   and   chromatin   modifier   associations   at  
region  1/2.  
The  observation   that  HDAC4   and  HDAC6   are   the  primary  1,25(OH)2D3   targets  but  not  
regulated   by   Gemini   supports   the   hypothesis   that   they   are   important   components   of  
1,25(OH)2D3-­‐‑mediated  cycling  of  the  IGFBP3  gene.  However,  it  has  to  be  taken  into  account  
that  the  dynamics  association  of  the  HDAC4  and  HDAC  6  was  observed  immediately  after  
ligand   treatment,   and   therefore   these   events   cannot   result   from   protein   products   of   the  
simultaneous   mRNA   induction   of  HDAC4   and  HDAC6.   Nevertheless,   the   simultaneous  
silencing  of   the  expression  of  both  HDAC4  and  HDAC6   resulted   in   linear   IGFBP3  mRNA  
accumulation,   which   confirms   the   role   of   both   proteins   in   the   1,25(OH)2D3-­‐‑mediated  
transcriptional  cycling  of  the  gene.  
The  study  did  not  analyze   the  differences   in  Gemini  and  1,25(OH)2D3-­‐‑induced   IGFBP3  
protein  accumulation.  Since  treatment  with  Gemini  evokes  stronger  mRNA  accumulation,  
it  can  be  expected  that  Gemini  induces  also  higher  protein  levels  compared  to  that  induced  
by  1,25(OH)2D3.  However,  the  observed  transcriptional  cycling  is  most  likely  not  observed  
as  fluctuation  of  protein  levels  of  IGFBP3  since  short  temporal  changes  in  mRNA  levels  are  
not  directly  reflecting  the  protein  levels.  The  physiological  impact  of  transcriptional  cycling  
is   rather   a   feedback   loop   mechanism   for   controlling   the   transcription   process.   This  
regulatory  mechanism  is  not  used  by  Gemini.  
In  conclusion,  1,25(OH)2D3  induces  cyclical  mRNA  induction  of  the  IGFBP3  gene,  which  
results  from  sequential  association  of  HDAC4,  HDAC6  and  VDR  to  genomic  VDR  binding  
loci.   For  Gemini   these  mechanisms   seem  not   to   apply,   and   thus   the  up-­‐‑regulation   of   the  
gene  is  stronger  and  linear.  This  provides  mechanistic  insight  into  how  1,25(OH)2D3  and  its  
synthetic  analog  mediate  their  growth  inhibitory  function  via  IGFBP3  induction.  
6.2 CANCER ASSOCIATED TARGET GENES OF 1,25(OH)2D3 
In  study  II,  three  genes  involved  in  the  control  of  cellular  proliferation,  G0S2,  CDKN1A  and  
MYC,  were  selected  as  examples   for  demonstrating   the  complex  nature  of  1,25(OH)2D3   in  
the  context  of  growth  inhibition.  The  selection  of  the  genes  was  based  on  the  evaluation  of  
data  from  a  transcriptome-­‐‑wide  microarray  and  ChIP-­‐‑seq  experiments  prepared  in  THP-­‐‑1  
monocytic  leukemia  cells  (81).  In  addition,  public  ENCODE  data  were  used  to  estimate  the  
size  of  the  chromosomal  domains  around  the  genes.  
The   response   of   the  G0S2   gene   to   1,25(OH)2D3   was   stronger   than   those   of   the   genes  
CDKN1A  and  MYC.  Interestingly,  in  macrophages  the  induction  of  G0S2  was  higher  than  in  
monocytes,   although   the   basal   expression   of   the   gene   increased   when   the   cells  
differentiated   into   macrophages.   In   most   cases   higher   basal   expression   leads   to   lower  
inducibility  of   the  gene,   as  observed  with   the  genes  CXCL8,  CXCL6   and  CXCL1   (III)   and  
ASAP2  (IV).  The  role  of  G0S2  protein  as  a  tumor  suppressor  gene  was  recently  established  
using  the  K562  leukemic  cellular  model  (95).  Therefore,  the  finding  of  study  II  that  G0S2  is  




promotes  a  reasonable  proportion  of  its  anti-­‐‑cancer  actions  through  G0S2  mRNA  induction.  
However,   in  THP-­‐‑1  cells   the  G0S2  gene   is  expressed,   thus  growth   inhibition  mediated  by  
G0S2  cannot  be  directly   compared   to  K562  cells,  where   it   is   suppressed   (95).   In  addition,  
both  the  role  of  G0S2  in  inhibiting  cell  proliferation  in  hematopoietic  stem  cells  (97)  and  its  
association  with  growth  arrest  of   adipocytes   (98)   are   consistent  with   the  observation   that  
the   G0S2   gene   is   more   strongly   expressed   in   macrophages,   which   do   not   proliferate  
anymore.  Analysis  of  VDR  ChIP-­‐‑seq  data  from  monocytes  and  macrophages  indicated  that  
G0S2  is  regulated  only  by  one  VDR  locus.  Interestingly,  the  same  VDR  binding  site  is  also  
occupied   in   all   other   publicly   available   VDR   ChIP-­‐‑seq   datasets   besides   that   from   colon  
cancer  cells  suggesting  that  the  gene  is  a  tissue-­‐‑wide  conserved  1,25(OH)2D3  target.  
In  macrophages  the  basal  expression  of  the  CDKN1A  gene  was  higher  than  in  monocytes  
but   the   inducibility  by  1,25(OH)2D3  was   reduced.   In  macrophages  none  of   the   three  VDR  
binding  sites  of  the  gene  was  occupied  suggesting  that  in  these  cells  the  gene  is  a  secondary  
1,25(OH)2D3  target.  Although  VDR  association  with  locus  1  of  the  CDKN1A  promoter  was  
observed  by  VDR  ChIP-­‐‑seq  in  B  cells  (82)  and  in  LPS-­‐‑stimulated  THP-­‐‑1  cells  (71),  it  could  
not   be   confirmed   by  ChIP-­‐‑qPCR   in  monocytes.  However,   the   observation   of   a   relatively  
faint  ChIP-­‐‑seq  signal  at  locus  1  was  accompanied  by  very  strong  FAIRE-­‐‑signal  (i.e.  highly  
accessible  chromatin)  in  the  absence  of  a  DR3-­‐‑type  motif.  This  suggests  that  VDR  interacts  
at   site   1   with   another   transcription   factor   and   does   not   directly   bind   to   DNA.   This  
interpretation  fits  with  the  observation  form  ChIP-­‐‑qPCR  experiments,  where  such  a  weak  
interaction  may  have  not  been  captured  under  the  used  conditions.  In  contrast,  the  binding  
of  VDR  to  the  two  remaining  loci  was  confirmed  by  ChIP-­‐‑qPCR  in  monocytes.  
Evidence   from   both   cell   culture   and   animal  models   verify   that   the   inhibition   of  MYC  
expression  suppresses  cancer  cell  growth  (121).  In  this  study,  the  observed  down-­‐‑regulation  
of   the  MYC  gene   in  monocytes   suggests   that  1,25(OH)2D3   inhibits   cellular  growth  via   the  
MYC   gene.   When   monocytes   differentiated   to   macrophages,   the   repressive   effect   of  
1,25(OH)2D3  on  the  MYC  gene  changed  unexpectedly  into  an  induction.  This  suggests  that  
in  macrophages,  which  are   terminally  differentiated,   the  Myc  protein  has  a  different   role  
than  in  undifferentiated  monocytes.  Furthermore,  the  prominent  VDR  association  at  site  1  
of   the  MYC   gene   was   down-­‐‑regulated   in   monocytes   in   response   to   1,25(OH)2D3,   which  
seems   to   be   recovered   at   60   min.   This   dynamic   VDR   association   is   supported   by   the  
previous  observations  at  the  two  VDR  binding  regions  on  IGFBP3  promoter  (see  study  I).  
VDR  binding  site  1  is  located  within  the  coding  region  of  the  MYC  gene,  so  that  temporal  
three-­‐‑dimensional   chromatin   associations   of   the   three   remaining  VDR  binding   sites  with  
the   transcription   machinery   may   increase   the   dynamic   response   observed   at   site   1.  
Interestingly,   site  1   is  not  occupied   in  macrophages,  and   therefore   the   regulation  of  VDR  
binding   to   this   site  may   have   an   important   role   in   triggering   the   events   that   switch   the  
down-­‐‑regulated  MYC   gene   in   monocytes   into   up-­‐‑regulated   gene   in   macrophages.   The  
public  VDR  ChIP-­‐‑seq  datasets  indicate  that  the  four  VDR  binding  sites  of  the  MYC  gene  are  
only  used  in  THP-­‐‑1  cells.  In  contrast  to  the  VDR  binding  profile  in  monocytes,  VDR  ChIP-­‐‑
seq   data   of   LPS-­‐‑stimulated   THP-­‐‑1   cells   (71)   suggests   that   VDR   is   only   associated   with  
sites  2,   3   and   4.   Thus,   an   evaluation  whether   the  MYC   gene   is   up-­‐‑   or  down-­‐‑regulated   in  
these  cells  would  give  more  information  about  importance  of  site  1.  
The  involvement  of  1,25(OH)2D3  in  the  regulation  of  the  three  studied  1,25(OH)2D3  target  
genes   controlling   cellular   growth,   G0S2,   CDKN1A   and   MYC,   demonstrates,   that   the  
hormone   has   a   complex   and   cell-­‐‑specific   role   in   growth   inhibition   of  monocytic   cells.   In  
monocytes,  1,25(OH)2D3  seems  to  promote  cellular  growth  inhibition  through  all  these  three  
genes,   although   the   effects   on   the   genes   CDKN1A   and   MYC   are   rather   modest.   For  
example,  dys-­‐‑regulation  of  Myc   signaling   is   found   in  most   types  of   cancers.   1,25(OH)2D3  
may  simply  enhance  the  transcriptional  control  of  MYC  expression  in  monocytes,  which  is  
observed  as  a  faint  down-­‐‑regulation  in  study  II.  Similarly,  if  the  magnitude  of  the  induction  




cell  cycle,  while  the  stronger  anti-­‐‑proliferative  effects  are  meditated  through  the  activation  
of  tumor-­‐‑suppressor  gene  G0S2.  
As   a   primary   1,25(OH)2D3   target,   G0S2   is   a   rather   simple   example,   as   it   is   strongly  
induced  in  both  monocytes  and  macrophages  and  is  controlled  by  only  one  VDR  binding  
site  close   to   its  TSS  region.  G0S2  displays   ligand-­‐‑inducible  chromatin  opening   in   its  VDR  
binding   site,   which   is   conserved   between   cell   types.   While   the   CDKN1A   gene   is   up-­‐‑
regulated  in  both  cell  types  but  demonstrates  a  rather  differential  recruitment  of  VDR  to  its  
binding   loci,   the  MYC   gene   reveals   significant   differences   in   both  mRNA   induction   and  
VDR  occupancy  when  monocytes  and  macrophages  are  compared.  These   results  propose  
that   each   gene   has   a   tissue-­‐‑   and   gene-­‐‑specific   complexity   in   regulation   mediated   by  
1,25(OH)2D3.  
6.3 REGULATION OF THE CHEMOKINE CLUSTER ON CHROMOSOME 4 BY 
1,25(OH)2D3 
Previous  VDR  ChIP-­‐‑seq  and  microarray  data  from  THP-­‐‑1  monocytes  suggested  CXCL8  as  
primary   1,25(OH)2D3   target   gene   (81).   Therefore,   in   study   III   the   responsiveness   of   the  
whole  CXCL  chemokine  gene  cluster  to  1,25(OH)2D3  was  analyzed  both  in  undifferentiated  
THP-­‐‑1   monocytes   and   in   PMA-­‐‑differentiated   macrophages.   The   study   confirmed   the  
CXCL8  gene  as  primary  up-­‐‑regulated  1,25(OH)2D3  target  gene  in  monocytes.  Moreover,  the  
study  described  that  the  neighboring  genes  CXCL6  and  CXCL1  were  up-­‐‑regulated  as  well,  
whilst  no  other  gene  of  the  cluster  was  expressed.  Moreover,  no  1,25(OH)2D3  induction  of  
the  expressed  flanking  genes  outside  the  CXCL  cluster  was  observed.  In  macrophages  the  
same   three   CXC   genes   were   up-­‐‑regulated   1,25(OH)2D3   targets,   but   showed   delayed  
responsiveness   with   reduced   inducibility.   However,   the   reduced   responsiveness   is  
accompanied  with  higher  basal  expression  and  therefore  already  the  lower  induction  of  the  
genes   leads   to   higher   copy   numbers   of   total   mRNA   synthesis   in   macrophages   than   in  
monocytes.  
Analysis   of   VDR   ChIP-­‐‑seq   data   from   monocytes   and   macrophages   suggested   that   a  
single   VDR   binding   site   downstream   of   the  CXCL8   gene   regulates   the   CXCL   cluster.   In  
addition,   DNA   looping  mediated   by   conserved,   insulating,   CTCF   binding   sites   suggests  
that  all  nine  CXC  chemokine  genes  belong  to  the  same  chromosomal  domain.  Interestingly,  
the  rather  high  FAIRE  signal   in  the  chromosomal  region  of  the  genes  CXCL8,  CXCL6  and  
CXCL1   suggest   that   in   monocytes   this   region   is   far   more   accessible   than   the   remaining  
CXCL   cluster.   The   CXCL4.1   gene,   which   is   located   between   CXCL6   and   CXCL1,   is   a  
platelet-­‐‑specific   chemokine,   which   is   most   likely   the   reason   why   it   is   not   expressed   in  
monocytes.  However,   this   study  suggests   that   the  CXCL4.1  gene  would  be  a  1,25(OH)2D3  
target  gene  in  tissues  where  it  is  expressed.  Furthermore,  the  observation  that  CXCL7  and  
CXCL3   are   expressed   in  macrophages,   but   are   not   induced,   suggests   that   shorter   CTCF-­‐‑
mediated   regulatory   loops,   such   as   a   loop   from   site   2   to   site   4,   are   dominant   at   least   in  
macrophages.  
The   observations   that   i)   the  VDR  binding   site   is   close   to   the   up-­‐‑regulated   genes,   ii)   it  
exhibits   ligand-­‐‑dependent   chromatin   opening,   iii)   it   contains   a   DR3-­‐‑type   motif   and   iv)  
CXCL8,  CXCL6  and  CXCL1  are  prominently  up-­‐‑regulated  after  ligand  treatment  of  the  cells  
confirms   that   these   genes   are   classical   1,25(OH)2D3   target   genes.   This   conclusion   is  
consistent   with   a   recent   study   (53),   where   CXCL8   was   found   as   an   up-­‐‑regulated  
1,25(OH)2D3   target   in   PMA-­‐‑differentiated  THP-­‐‑1  macrophages.   In   addition,   in   that   study  
mycobacterium  infection  led  to  the  induction  of  CXCL8,  which  could  be  further  enhanced  
by   stimulation   with   1,25(OH)2D3.   This   suggests   that   1,25(OH)2D3   promotes   CXCL8  
expression   in  THP-­‐‑1   cells   even   after   the   gene   is   induced  by  PMA  or   other   inflammatory  
signals.   However,   the   results   in   THP-­‐‑1   cells   seem   to   be   contradictory   to   the   previous  




mediated   induction   of   CXCL8   in   primary   pro-­‐‑inflammatory   monocytes   from   type   2  
diabetes   patients.  However,   the   study   did   not   evaluate  whether   the   reduction   in  CXCL8  
inducibility   was   a   primary   or   secondary   effect   of   1,25(OH)2D3.   Treatment   with   IFN-­‐‑γ  
stimulates   the   transcription  factor  NF-­‐‑κB,  which  strongly  up-­‐‑regulates  CXCL8  expression.  
Since  1,25(OH)2D3  inhibits  NF-­‐‑κB-­‐‑mediated  target  gene  transcription  (48),  the  contradictory  
observations   may   reflect   a   1,25(OH)2D3-­‐‑mediated   inhibition   of   IFN-­‐‑γ-­‐‑induced   NF-­‐‑κB  
transcription  rather  than  a  primary  effect  of  VDR  on  transcription.  This  is  then  observed  as  
reduced   inducibility  of  CXCL8.   In  addition,   the  response  of   the  CXCL8  gene  may  depend  
on   the   cellular   system   suggesting   that   THP-­‐‑1   cells   show   different   results   than   primary  
monocytes.  
The  general   actions  of   1,25(OH)2D3  are   considered   to  be  anti-­‐‑inflammatory,   so   that   the  
observed   up-­‐‑regulation   of   the   inflammatory   chemokines   on   CXCL   cluster   seems   to   be   a  
contradiction.   However,   as   the   recent   study   (53)   suggested,   a   supporting   role   of  
1,25(OH)2D3   in   chemokine   secretion   requires   also   an   inflammatory   signal.   Since  
1,25(OH)2D3  is  also  able  to  control  the  inflammatory  responses  via  the  repression  of  NF-­‐‑κB,  
the   observation   in   study   III   suggests   that   1,25(OH)2D3   has   complex   time-­‐‑   and   signal-­‐‑
dependent   modulatory   effects   on   inflammatory   reactions.   In   addition,   the   induction   by  
1,25(OH)2D3  is  far  lower  than  that  of  inflammatory  signals,  so  that  the  effects  of  1,25(OH)2D3  
may  be  only  supportive.  
In   contrast   to   the   observations   in   study   II,   where   1,25(OH)2D3   promoted   anti-­‐‑cancer  
effects   in   monocytes,   the   observations   from   study   III   suggest   that   1,25(OH)2D3   would  
promote  cancer  growth  through  the  induction  of  the  angiogenic  CXC  chemokines  in  same  
cells.   However,   the   physiological   consequence   of   transcriptional   up-­‐‑regulation   of   the  
inflammatory   chemokines   in   context   of   cancer   is   not   clear,   since   their   main   function   is  
neutrophil  chemoattraction.  However,  the  net  effect  of  1,25(OH)2D3  in  this  cell  line  is  anti-­‐‑
proliferative  despite  the  up-­‐‑regulation  of  angiogenic  CXC  chemokines.  
The  findings  that  both  in  monocytes  and  in  PMA-­‐‑differentiated  macrophages  the  genes  
CXCL8,  CXCL6  and  CXCL1  are  primary  targets  of  1,25(OH)2D3  implies  a  more  differential  
aspect  on  the  modulation  of  the  inflammatory  reaction  by  1,25(OH)2D3.  The  study  provided  
more  evidence  for  a  role  of  vitamin  D  in  supporting  immune  system  function.  
6.4 THE ASAP2 GENE LOCUS 
Similarly   to   studies   II   and   III,   VDR  ChIP-­‐‑seq   and  microarray   data   from  THP-­‐‑1   cells   (81)  
highlighted  an  interesting  genomic  region,  the  ASAP2  gene  locus  on  chromosome  2,  which  
was   further   characterized   in   study   IV.   In   both   undifferentiated   THP-­‐‑1   monocytes   and  
PMA-­‐‑differentiated   macrophages   the   ASAP2   gene   was   confirmed   as   the   sole   primary  
1,25(OH)2D3  target  gene  of  this  locus.  
The   expression   levels   of   all   genes   within   the   ASAP2   locus   were   characterized   in  
monocytes   and   macrophages.   While   the   neighboring   genes   showed   constant   basal  
expression   levels   in   both   cell   types,  ASAP2   mRNA   expression   increased   80-­‐‑fold   during  
differentiation   from  monocytes   into  macrophages.  The  responsiveness  of   the  ASAP2  gene  
to   1,25(OH)2D3  was   reduced   in  macrophages,  where   it   reached   only   a   2.6-­‐‑fold   induction  
after  8  h  of   treatment.   In  contrast,   in  monocytes   the  gene  was  more  prominently   induced  
already   after   2.5  h.   The   observation   that   a   gene   is   less   induced   but   has   a   higher   basal  
expression   in   the  given   cellular  model,   parallels   the  previous  observation   concerning   the  
CXCL8  gene  (III).  Analysis  of  VDR  ChIP-­‐‑seq  data  suggested  three  VDR  binding  sites  54,  436  
and  574  kb  downstream  of  the  ASAP2  gene,  which  were  confirmed  by  ChIP-­‐‑qPCR  in  both  
cellular   systems.   In   addition,   public   data   for   DNA   looping   mediated   by   CTCF   (142)  
indicated  that  the  closest  VDR  binding  site  (peak  1,  54  kb  downstream)  and  the  ASAP2  TSS  
are  located  on  the  same  chromosomal  domain.  The  VDR  binding  profile  also  indicated  very  




connects  ASAP2   into  all  three  VDR  binding  sites,  but  it  remains  unanswered  whether  this  
regulatory   loop   is   used   also   in   THP-­‐‑1   cells.   In   the   future,   VDR   ChIA-­‐‑PET   data   have   to  
demonstrate   VDR-­‐‑mediated   chromatin   looping   after   induction   by   1,25(OH)2D3   and   will  
provide  more  information  about  the  role  of  the  two  VDR  loci.  
None  of  the  ASAP2  neighboring  genes,  ITGB1BP1,  CPSF3,  IAH1,  ADAM17,  YWHAQ  or  
TAF1B,  responded  to  short  term  1,25(OH)2D3  treatment  despite  the  presence  of  three  VDR  
binding  loci  in  their  vicinity.  Only  after  24  h  of  1,25(OH)2D3  treatment  there  was  found  to  be  
some  minor  induction  of  the  genes  IAH1,  ADAM17  and  YWHAQ  in  monocytes  suggesting  
that  these  genes  may  be  weak  secondary  targets  of  1,25(OH)2D3.  However,  it  is  possible  that  
these  downstream  effects  are  mediated  by  primary  VDR  target  genes  and  may  benefit  from  
VDR-­‐‑induced  chromatin  opening  that  would  result  in  increased  accessibility  of  these  sites  
to  other  transcription  factors.  
Interestingly,   FAIRE-­‐‑seq   data   from   THP-­‐‑1   cells   (86)   demonstrated   that   all   three   VDR  
binding   sites   within   the  ASAP2   region   display   1,25(OH)2D3-­‐‑induced   chromatin   opening.  
Genome-­‐‑wide   there   are   only   some   160   of   such  VDR   loci.   These  VDR   binding   sites   have  
2  times  more  likely  a  DR3-­‐‑type  motif  below  their  VDR  peak  summits  than  average  binding  
sites.   Accordingly,   all   three   sites   of   the  ASAP2   locus   contain   a   DR3-­‐‑type   sequence.   This  
suggests   that   VDR   binding   to   these   sites   is   more   stable   than   to   an   average   VDR   locus.  
Therefore,  these  sites  may  constitute  special  attraction  points  for  VDR  to  the  genome.  
In  conclusion,  study  IV  demonstrated  that   the  genomic  region  around  the  ASAP2  gene  
contains   three   ligand-­‐‑inducible   DR3-­‐‑type   motif-­‐‑containing   VDR   binding   sites,   which  
display   1,25(OH)2D3-­‐‑induced   chromatin   opening.   The   study   confirmed   that   the   ASAP2  
gene  is  the  only  primary  1,25(OH)2D3  target  of  the  three  VDR  sites  both  in  monocytes  and  
in  macrophages.  
6.5 VDR BINDING PROFILE RELATED TO REGULATORY DOMAINS IN 
MONOCYTES AND MACROPHAGES 
1,25(OH)2D3   target   genes   greatly   vary   in   the   size   of   their   regulatory   domains   formed   by  
CTCF-­‐‑mediated  DNA  looping  as  well  as  the  number  of  genes  and  VDR  binding  loci  within  
these   loops.   Hence,   it   is   clear   that   each   gene   has   its   customized   regulatory   scenario  
mediated  by  VDR  and  chromatin  organization.  For  example,  in  the  CXCL  cluster,  one  VDR  
binding  site  causes  rapid  up-­‐‑regulation  of  three  CXCL  genes  (III),  whilst  at  the  ASAP2  locus  
three   prominent   VDR   binding   sites  mediate   the   up-­‐‑regulation   of   only   one   gene   (IV).   In  
contrast,  the  chromatin  loop  around  the  MYC  gene  (II)  is  about  10  times  larger  than  that  of  
the  CXCL  cluster  or  the  ASAP2  locus.  However,  the  chromosomal  region  around  the  MYC  
gene  contains  only  a  few  genes,  i.e.  it  is  located  within  a  gene  desert  area,  which  is  exposed  
to  a  variety  of  regulatory  signals.  For  example,  a   large  number  of  cancer-­‐‑associated  SNPs  
are  identified  in  a  region  located  upstream  of  the  MYC  TSS,  which  is  less  than  1  Mb  in  size  
(148).   SNPs   located   in   this   region   are   among   the  most   important   cancer-­‐‑associated   SNPs  
and   affect   a   large   number   of   cancer   cases   at   the   population   level   (148).   The   presence   of  
many  VDR  binding  sites  at  the  MYC  locus,  some  of  which  are  located  fairly  distant  from  the  
gene’s  TSS,  corresponds  with  the  very  pleiotropic  regulation  of  the  MYC  gene.  
Furthermore,   in   the   CXCL   cluster   all   expressed   genes   belong   to   the   same   regulatory  
domain  and  show  similar  response  to  1,25(OH)2D3  treatment.  This  means  that  in  that  locus,  
CTCF-­‐‑mediated  regulatory  looping  seems  to  determine  the  target  genes  of  VDR.  However,  
in  the  ASAP2  locus  six  non-­‐‑responsive  genes  are  expressed  in  close  vicinity  of  1,25(OH)2D3  
inducible  VDR  binding   loci.   The   region   including  most   of   the   non-­‐‑responsive   genes   and  
two  VDR  binding  sites  (excluding  the  ASAP2  gene  and  its  most  inducible  VDR  site)  seems  
to  be  located  between  the  main  chromatin  loops  upstream  and  downstream  of  the  region.  
This   observation   suggests   that   regulatory   domains   determined   by   CTCFs   are   not  




addition,  the  two  VDR  binding  sites  do  not  induce  any  primary  response  of  nearby  located  
genes   and   are   therefore   apparently   non-­‐‑functional,   despite   displaying   1,25(OH)2D3  
inducible  binding.  Unfortunately,  the  present  study  could  not  uncover  why  VDR  is  active  
at  these  sites.  
Future  VDR  ChIA-­‐‑PET  data  will  provide  a  better  tool  for  evaluating  chromatin  looping  
and   the   relation   of   VDR   binding   locations   to   target   gene   induction.   It   will   demonstrate  
chromatin   looping   around   VDR   in   cases   where   present   CTCF   data   is   not   applicable.  
Moreover,   it   will   provide   details   for   the   function   of   single   VDR   binding   sites   in   cases,  
which   remained   undetermined   in   the   projects   of   this   thesis,   such   as   the   two   distal   VDR  
binding   sites  of   the  ASAP2   locus.   Finally,   it  will  provide   information  about   the   temporal  
three  dimensional  chromatin  structure  in  response  to  1,25(OH)2D3  treatment.  
6.6 VITAMIN D TARGET GENES IN MONITORING THE VITAMIN D 
RESPONSE OF HUMAN INDIVIDUALS 
Some   primary   VDR   target   genes,   such   as   G0S2   (II),   display   a   similar   response   to  
1,25(OH)2D3  treatment  in  both  monocytes  and  macrophages,  and  are  regulated  by  the  VDR  
binding  region  that  is  occupied  in  other  cell  lines  based  on  public  VDR  ChIP-­‐‑seq  data.  This  
suggests  that  these  genes  are  also  regulated  by  the  same  VDR  binding  sites   in  most  other  
tissues.  A  recent  harmonized  analysis  of  all  public  VDR  ChIP-­‐‑seq  experiments  (71)  resulted  
in   a   short   list   of   55   genomic   loci   that   are   occupied   by  VDR   in   all   these   six   cell   types.   In  
study   V,   which   was   performed   in   human   SGBS   pre-­‐‑adipocytes,   four   genomic   regions  
containing   the   genes  DUSP10,  TRAK1,  NRIP1   and  THBD  were   selected   as   representative  
examples.  
As  expected,  based  on  extrapolating  the  conservation  of  the  VDR  binding  loci,  the  study  
confirmed  that   the  four  genes  chosen  are  primary  1,25(OH)2D3  targets  as  well   in  the  used  
pre-­‐‑adipocyte  cell  model,  and  regulated  by  the  conserved  VDR  binding  site.  Since  the  genes  
have  been  previously  identified  as  primary  target  genes  in  monocytes  (81),  the  observation  
suggests  that  these  conserved  VDR  target  genes  are  responding  to  1,25(OH)2D3  also  in  most  
other  tissues  and  cells  expressing  VDR.  As  exemplified  by  the  divergent  biological  function  
among   the   four   studied   genes,  THBD   encoding   for   an   anti-­‐‑coagulant   glycoprotein   (149),  
TRAK1   coding  for  an   intracellular  adaptor  molecule   (150),  DUSP10   coding  for  a  mitogen-­‐‑
activated   protein   kinase-­‐‑specific   phosphatase   (151)   and  NRIP1   coding   for   a   nuclear   co-­‐‑
activator  (152),  1,25(OH)2D3  has  pleiotropic  actions  in  the  control  of  cellular  signaling.  
Since  there  is  increasing  evidence  showing  that  individual  responses  to  vitamin  D3  vary  
considerably,   molecular   biomarkers,   such   as   the   ubiquitous   1,25(OH)2D3   target   genes  
DUSP10,   TRAK1,   NRIP1   and   THBD,   are   needed   for   the   molecular   monitoring   of   the  
vitamin  D   status   of   human   individuals.   In   study   V,   the   assumption   that   changes   in   the  
expression   levels   of   these   genes   can   be   used   for  monitoring   vitamin  D   status  was   tested  
with  adipose  tissue  samples  of  47  participants  of  the  vitamin  D3  intervention  trial  VitDmet  
(NCT01479933,   ClinicalTrials.gov).   Changes   in   study   participants’   serum   25(OH)D3  
concentrations   were   compared   to   the   changes   in   gene   expression   levels   during   the  
intervention.   After   the   study   participants   were   sorted   by   their   responsiveness   of   gene  
expression  in  relation  to  changes  of  25(OH)D3  concentration,  it  was  found  that  the  DUSP10  
gene   is   the   most   comprehensive   biomarker   among   the   investigated   genes   showing   the  
strongest  correlation  between  the  investigated  changes.  Using  DUSP10  as  a  marker,  30  out  
of   47   individuals   showed   a   significant   correlation   (r2>0.5)   between   change   in   serum  
25(OH)D3   level   and   change   in   DUSP10   expression.   When   using   the   genes   TRAK1   and  
NRIP1  as  markers,  the  genes  identified  the  same  subgroup  of   individuals  as  DUSP10,  but  
captures   with   the   same   correlation   threshold   (r2>0.5)   only   23   and   22   of   the   47   study  




25(OH)D3  changes  in  a  different  subgroup  of  participants.  From  22  individuals  that  showed  
THBD  response,  only  13  were  included  into  the  group  defined  by  the  three  other  genes.  
In  the  used  pre-­‐‑adipocyte  cell  model  the  THBD  gene  turned  out  to  be  more  responsive  to  
1,25(OH)2D3   treatment   than   the   three   other   genes   examined   in   the   study.   Since   THBD  
inducibility  was   also   observed   in   other   public   datasets,   it  was   selected   into   the   previous  
study  (13),  which  suggested  the  genes  THBD  and  CD14  as  the  most  significant  single  genes  
associated  with   the  vitamin  D   status  of  human   individuals.   Furthermore,   in   a   study   that  
measured   combined   THBD   and   CD14   expression   level   changes   in   PBMCs   and   adipose  
tissue  samples,  both  genes  were  used  to  monitor  benefits  after  vitamin  D3  supplementation  
(14).  However,  study  V  found  that  the  DUSP10  gene  identified  more  vitamin  D3  responsive  
individuals  than  the  THBD  gene  and  the  correlations  of  all  four  genes  in  linear  regression  
analysis  showed  far  higher  significance  levels  than  the  previous  study.  This  was  possible  by  
focusing   on   highly   expressed   single   genes   that   were   analyzed   in   only   one   tissue.   Since  
THBD   expression   in   adipose   tissue   is   lower   than   that   of   the   three   other   genes,  
measurements   of   the   latter   genes   are   probably   more   stable.   In   addition,   genes   such   as  
CYP24A1   that  show  very  high   inducibility   in  pre-­‐‑adipocytes,  are  most   likely  representing  
rapid  changes  in  their  expression  levels  in  biological  samples  as  well.  Therefore  the  genes  
that   show   high   inductions   with   low   basal   expression   levels   are   not   the   most   suitable  
biomarkers,   but   rather   the   modestly   induced   genes   with   high   basal   expression,   such  
observed  with  DUSP10.  
The  results  of  study  V  suggest  that  individuals,  who  are  characterized  by  highly  induced  
THBD   expression,   form   a   distinct   group   from   the   responders   based   on   the   modestly  
induced  genes  DUSP10,  TRAK1   and  NRIP1.  This   raises   the  question  whether   individuals  
could   be   categorized   into   slow   and   rapid   responder   groups,   based   on   their   target   gene  
response.  In  order  to  reliably  evaluate  this  possibility,  repeated  measurements  shortly  after  
vitamin  D3  supplementation  are  needed.  Therefore,  further  studies  will  give  more  statistical  
power   to   evaluate   the   inter-­‐‑individual   variability   and   allow   further   categorization   of  
individuals   based   on   their   responsiveness   to   vitamin  D3   supplementation.   However,   the  
main   observation   of   study   V,   demonstrating   that   some   VDR   target   genes   in   adipocytes  
show  correlation  already  within  five  months  between  the  measuring  points,  indicates  that  
single  target  genes  can  be  used  as  biomarkers  for  measuring  individual  vitamin  D3  status.    
Among   the   30   individuals   that   showed   DUSP10   response   to   vitamin   D3,   the   basal  
25(OH)D3   levels   at   the   start   of   the   intervention   varied   between   36.9   to   73.6  nM.  
Interestingly,   only   3   of   the   30   individuals   had   the   serum   25(OH)D3   levels   below   50  nM  
which  can  be  considered  as  insufficiency  of  vitamin  D3  according  IoM  (8).  The  observation  
suggests   that   rather   the   individual’s   transcriptomic   responsiveness   to   vitamin   D3  
supplementation  than  a  fixed  serum  25(OH)D3  level  should  be  considered  when  vitamin  D3  
supplementation  is  recommended.  
Most  of  the  other  VDR  target  genes  characterized  in  this  thesis  are  probably  unsuitable  
as  biomarkers.  For  example,   the  CXC  chemokines   (III)  are  highly  and  rapidly   induced  by  
various  inflammatory  stimuli.  Therefore,  most  likely  the  expression  changes  of  these  genes  
represent   the   individual’s   inflammatory  status.   In  addition,   the  cancer-­‐‑associated  primary  
target  genes  MYC   and  CDKN1A   showed  differential  VDR-­‐‑mediated   transcription  already  
in  THP-­‐‑1  models   (II)   and   therefore   the  observations  may  not  be   applied   to  other   tissues.  
However,   in   contrast   to   ASAP2   (IV)   that   is   regulated   by   three   VDR   binding   sites,   the  
primary   target  G0S2   (II)   is   regulated  by   one   conserved  VDR  binding   region   and  may  be  
suitable  for  measuring  the  vitamin  D3  status  in  tissues  where  it  is  expressed.  
In  conclusion,  study  V  demonstrated  a  new  approach  for  predicting  1,25(OH)2D3  target  
genes  based  on  conservation  of  genomic  VDR  binding  sites.  In  addition,  it  was  shown  that  
expression   changes   of   such   ubiquitous   1,25(OH)2D3   targets   can   be   used   as   molecular  
biomarkers   for   the   vitamin  D3   responsiveness   in   human   adipocytes   and  other   tissue   and  
cell  types.  




7  Summary  and  Conclusion  
In   this   thesis   the  molecular   actions   of   1,25(OH)2D3   on   several   aspects   of   gene   regulation  
were  studied.  The  main  findings  of  this  study  can  be  concluded  as  follows:  
  
  
I 1,25(OH)2D3  induces  a  dynamic  and  orchestrated  mRNA  accumulation  profile  of  
the  IGFBP3  gene.  The  dynamic  nature  of  the  transcription  results  from  sequential  
association  of  HDAC4,  HDAC6  and  VDR  to  VDR  binding  loci  leading  to  repeated  
induction  of  IGFBP3  mRNA  production.  However,  this  feedback  loop  mechanism  
does  not  to  apply  for  the  induction  of  the  gene  by  the  1,25(OH)2D3  analog  Gemini.  
  
II The   example   of   the   genes   G0S2,   CDKN1A   and   MYC,   which   have   important  
functions  in  cellular  growth,  established  a  tissue-­‐‑  and  gene-­‐‑specific  scenario  in  the  
1,25(OH)2D3-­‐‑mediated   regulation   of   the   genes.   This   demonstrates   that   no   single  
gene  is  responsible  for  the  control  of  cellular  growth  by  1,25(OH)2D3.  
  
III The   findings   that   the   chemokine   genes  CXCL8,  CXCL6   and  CXCL1   are   primary  
targets   of   1,25(OH)2D3   in   both   monocytes   and   macrophages   provides   more  
evidence  for  role  of  vitamin  D3/1,25(OH)2D3  in  supporting  the  immune  system  in  
its  fight  against  microbes  and  cancer.  
  
IV The  genomic  region  containing  ASAP2  gene  is  regulated  by  three  ligand-­‐‑inducible  
DR3-­‐‑type  motif-­‐‑containing  VDR  binding   sites   and   exhibits   1,25(OH)2D3-­‐‑induced  
chromatin  opening.  The  sole  function  of  the  VDR  regulation  at  the  locus,  both  in  
monocytes  and  in  macrophages,  is  the  up-­‐‑regulation  of  the  ASAP2  gene.  
  
V Conserved  genomic  VDR  binding  sites  can  be  used  to  predict  1,25(OH)2D3  target  
genes   in   other   tissues   and   cell   types,   as   demonstrated   for   the   genes  DUSP10,  
TRAK1,  NRIP1   and  THBD.   Such   ubiquitous   1,25(OH)2D3   targets   can   be   used   as  




The  present   study  provides   further   insight   into   the  mechanisms  of   gene   regulation  by  
1,25(OH)2D3.   I   demonstrated   that   the   regulation   of   gene   expression   by   1,25(OH)2D3   is  
strictly   controlled   dynamic   process.   At   the   example   of   several   1,25(OH)2D3   target   genes  
involved  in  controlling  immune  function  and  cellular  growth  I  could  show  that  chromatin  
activation,   VDR   binding   and   transcriptional   activation   take   place   in   region-­‐‑   and   gene-­‐‑  
specific  manner.  Finally,  I   indicated  that  the  information  from  primary  1,25(OH)2D3  target  
gene  expression  can  be  applied  to  human  individuals,  in  order  to  evaluate  their  response  to  
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Vitamin D is an important 
regulator of gene expression. 
Epidemiological evidence suggests 
a protective role of vitamin 
D against various diseases. 
Therefore, the molecular basis of 
vitamin D signaling needs to be 
elucidated. This thesis investigated 
the regulation of key vitamin D 
target genes, in order to provide 
further insight into the role of 
vitamin D in cancer and immunity. 
In this context it was found that 
certain vitamin D target genes 
can be used as biomarkers for 
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